CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | hydroperoxy group |
|
Accession: | CHEBI:29792
|
browse the term
|
Synonyms: | exact_synonym: | dioxidanyl; hydroperoxy |
| related_synonym: | -OOH; Formula=HO2; SMILES=O(O[H])* |
|
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
increases response to substance |
ISO |
GPX1 protein results in increased susceptibility to 12-HPETE |
CTD |
PMID:11115402 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
increases chemical synthesis |
ISO |
GPX4 protein results in increased chemical synthesis of 12-HPETE |
CTD |
PMID:11115402 |
|
NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
12-HPETE inhibits the reaction [Sodium Salicylate inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]]; 12-HPETE inhibits the reaction [Sodium Salicylate results in decreased activity of PTGS2 protein] |
CTD |
PMID:12538810 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
|
G |
Cat |
catalase |
increases expression |
ISO |
13-hydroperoxy-9,11-octadecadienoic acid results in increased expression of CAT protein |
CTD |
PMID:10946007 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cav1 |
caveolin 1 |
increases expression |
ISO |
13-hydroperoxy-9,11-octadecadienoic acid results in increased expression of CAV1 mRNA |
CTD |
PMID:27257344 |
|
NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP |
[13-hydroperoxy-9,11-octadecadienoic acid co-treated with 2-chloro-5-nitrobenzanilide] results in increased expression of CCL2 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with 2-chloro-5-nitrobenzanilide] results in increased expression of CCL2 protein; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of CCL2 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of CCL2 protein |
CTD |
PMID:22135674 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
EXP |
[13-hydroperoxy-9,11-octadecadienoic acid co-treated with 2-chloro-5-nitrobenzanilide] results in increased expression of EGR1 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with 2-chloro-5-nitrobenzanilide] results in increased expression of EGR1 protein; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of EGR1 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of EGR1 protein |
CTD |
PMID:22135674 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
increases expression |
EXP |
13-hydroperoxy-9,11-octadecadienoic acid results in increased expression of PPARA protein |
CTD |
PMID:22135674 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression |
EXP |
13-hydroperoxy-9,11-octadecadienoic acid results in increased expression of PPARG protein |
CTD |
PMID:22135674 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
|
G |
Abl1 |
ABL proto-oncogene 1, non-receptor tyrosine kinase |
increases expression |
ISO |
perfosfamide results in increased expression of ABL1 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 3:14,979,853...15,083,065
Ensembl chr 3:14,979,853...15,083,065
|
|
G |
Actb |
actin, beta |
decreases expression |
ISO |
perfosfamide results in decreased expression of ACTB mRNA |
CTD |
PMID:19429390 |
|
NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877
|
|
G |
Agt |
angiotensinogen |
decreases response to substance |
ISO |
AGT protein results in decreased susceptibility to perfosfamide |
CTD |
PMID:11034089 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
multiple interactions increases response to substance |
ISO |
Acetylcysteine inhibits the reaction [perfosfamide results in increased localization of AIFM1 protein]; perfosfamide results in increased expression of and results in increased localization of AIFM1 protein AIFM1 results in increased susceptibility to perfosfamide |
CTD |
PMID:18034189 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Akr1b10 |
aldo-keto reductase family 1 member B10 |
affects response to substance |
ISO |
AKR1B10 protein affects the susceptibility to perfosfamide |
CTD |
PMID:18473730 |
|
NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
decreases response to substance |
ISO |
ALDH1A1 protein results in decreased susceptibility to perfosfamide |
CTD |
PMID:8662658 PMID:16614850 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldh1a2 |
aldehyde dehydrogenase 1 family, member A2 |
decreases response to substance |
ISO |
ALDH1A2 protein results in decreased susceptibility to perfosfamide |
CTD |
PMID:22079344 |
|
NCBI chr 8:71,877,850...71,957,107
Ensembl chr 8:71,877,850...71,957,107
|
|
G |
Aldh1b1 |
aldehyde dehydrogenase 1 family, member B1 |
affects response to substance |
ISO |
ALDH1B1 protein affects the susceptibility to perfosfamide |
CTD |
PMID:18473730 |
|
NCBI chr 5:60,063,370...60,068,378
Ensembl chr 5:60,063,225...60,068,378
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
decreases response to substance |
ISO |
ALDH2 protein results in decreased susceptibility to perfosfamide |
CTD |
PMID:22079344 |
|
NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521
|
|
G |
Aldh3a1 |
aldehyde dehydrogenase 3 family, member A1 |
decreases response to substance |
ISO |
ALDH3A1 protein results in decreased susceptibility to perfosfamide |
CTD |
PMID:16614850 |
|
NCBI chr10:45,892,993...45,902,680
Ensembl chr10:45,892,924...45,902,681
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
decreases expression |
EXP |
perfosfamide results in decreased expression of APEX1 mRNA |
CTD |
PMID:11754170 |
|
NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions affects folding increases expression |
ISO |
Acetylcysteine inhibits the reaction [perfosfamide affects the folding of BAX protein]; Acetylcysteine inhibits the reaction [perfosfamide results in increased localization of BAX]; perfosfamide results in increased expression of and results in increased localization of BAX perfosfamide results in increased expression of BAX protein |
CTD |
PMID:16488414 PMID:18034189 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
increases expression |
ISO |
perfosfamide results in increased expression of BBC3 mRNA |
CTD |
PMID:17068108 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bmpr1b |
bone morphogenetic protein receptor type 1B |
decreases expression |
ISO |
perfosfamide results in decreased expression of BMPR1B mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 2:230,538,252...230,871,077
Ensembl chr 2:230,541,558...230,871,368
|
|
G |
C1d |
C1D nuclear receptor corepressor |
increases expression |
ISO |
perfosfamide results in increased expression of C1D mRNA |
CTD |
PMID:19429390 |
|
NCBI chr14:91,660,951...91,673,177
Ensembl chr14:91,660,989...91,672,852
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions |
ISO |
perfosfamide results in increased activity of CASP3 perfosfamide promotes the reaction [TNF results in increased activity of CASP3 protein] |
CTD |
PMID:16488414 PMID:17434952 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
increases activity |
ISO |
perfosfamide results in increased activity of CASP9 protein |
CTD |
PMID:16488414 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
perfosfamide results in increased expression of CDKN1A perfosfamide results in increased expression of CDKN1A mRNA; perfosfamide results in increased expression of CDKN1A protein |
CTD |
PMID:17068108 PMID:18034189 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cxcl9 |
C-X-C motif chemokine ligand 9 |
decreases expression |
ISO |
perfosfamide results in decreased expression of CXCL9 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr14:15,722,868...15,727,779
Ensembl chr14:15,722,908...15,728,435
|
|
G |
E2f1 |
E2F transcription factor 1 |
increases expression |
ISO |
perfosfamide results in increased expression of E2F1 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
Egr1 |
early growth response 1 |
decreases expression |
ISO |
perfosfamide results in decreased expression of EGR1 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Endog |
endonuclease G |
increases response to substance multiple interactions |
ISO |
ENDOG results in increased susceptibility to perfosfamide Acetylcysteine inhibits the reaction [perfosfamide results in increased localization of ENDOG protein]; perfosfamide results in increased expression of and results in increased localization of ENDOG protein |
CTD |
PMID:18034189 |
|
NCBI chr 3:13,449,113...13,451,715
Ensembl chr 3:13,449,086...13,451,932
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
increases expression |
ISO |
perfosfamide results in increased expression of EPAS1 protein |
CTD |
PMID:23251655 |
|
NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228
|
|
G |
Epha6 |
Eph receptor A6 |
decreases expression |
ISO |
perfosfamide results in decreased expression of EPHA6 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr11:39,757,501...40,708,901
Ensembl chr11:39,757,181...40,698,311
|
|
G |
Eya1 |
EYA transcriptional coactivator and phosphatase 1 |
decreases expression |
ISO |
perfosfamide results in decreased expression of EYA1 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 5:4,863,501...5,101,483
Ensembl chr 5:4,955,543...5,101,483
|
|
G |
Faslg |
Fas ligand |
increases expression |
ISO |
perfosfamide results in increased expression of FASLG mRNA; perfosfamide results in increased expression of FASLG protein |
CTD |
PMID:14760101 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Foxf1 |
forkhead box F1 |
affects expression |
ISO |
perfosfamide affects the expression of FOXF1 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr19:49,153,949...49,157,741
Ensembl chr19:49,153,699...49,157,738
|
|
G |
Gjc1 |
gap junction protein, gamma 1 |
increases expression |
ISO |
perfosfamide results in increased expression of GJC1 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr10:87,758,192...87,785,443
Ensembl chr10:87,760,528...87,785,867
|
|
G |
Gli2 |
GLI family zinc finger 2 |
decreases expression |
ISO |
perfosfamide results in decreased expression of GLI2 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr13:29,946,882...30,163,589
Ensembl chr13:29,946,809...30,163,574
|
|
G |
Hes1 |
hes family bHLH transcription factor 1 |
increases expression |
ISO |
perfosfamide results in increased expression of HES1 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr11:70,705,763...70,708,176
Ensembl chr11:70,705,764...70,708,192
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
increases expression |
ISO |
perfosfamide results in increased expression of HIF1A mRNA; perfosfamide results in increased expression of HIF1A protein |
CTD |
PMID:19429390 PMID:23251655 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hoxa11 |
homeobox A11 |
decreases expression |
ISO |
perfosfamide results in decreased expression of HOXA11 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 4:81,342,527...81,346,189
Ensembl chr 4:81,342,528...81,346,232
|
|
G |
Hoxa13 |
homeo box A13 |
increases expression |
ISO |
perfosfamide results in increased expression of HOXA13 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 4:81,358,956...81,361,091
Ensembl chr 4:81,358,956...81,361,091
|
|
G |
Hoxd10 |
homeo box D10 |
increases expression |
ISO |
perfosfamide results in increased expression of HOXD10 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 3:59,594,516...59,597,725
Ensembl chr 3:59,594,516...59,597,725
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
decreases expression |
ISO |
perfosfamide results in decreased expression of HRAS mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
|
|
G |
Kl |
Klotho |
decreases expression |
ISO |
perfosfamide results in decreased expression of KL mRNA |
CTD |
PMID:19429390 |
|
NCBI chr12:490,402...531,417
Ensembl chr12:490,399...530,080
|
|
G |
Lig3 |
DNA ligase 3 |
decreases expression |
EXP |
perfosfamide results in decreased expression of LIG3 mRNA |
CTD |
PMID:11754170 |
|
NCBI chr10:67,717,808...67,741,141
Ensembl chr10:67,717,812...67,798,414
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
increases expression |
ISO |
perfosfamide results in increased expression of MDM2 |
CTD |
PMID:18034189 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
decreases expression |
EXP |
perfosfamide results in decreased expression of MGMT mRNA |
CTD |
PMID:11754170 |
|
NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756
|
|
G |
Mlh1 |
mutL homolog 1 |
decreases expression |
EXP |
perfosfamide results in decreased expression of MLH1 mRNA |
CTD |
PMID:11754170 |
|
NCBI chr 8:111,196,468...111,233,721
Ensembl chr 8:111,196,468...111,233,617
|
|
G |
Mpg |
N-methylpurine-DNA glycosylase |
decreases expression |
EXP |
perfosfamide results in decreased expression of MPG mRNA |
CTD |
PMID:11754170 |
|
NCBI chr10:15,396,246...15,402,528
Ensembl chr10:15,395,782...15,402,520
|
|
G |
Mre11 |
MRE11 homolog, double strand break repair nuclease |
decreases expression |
EXP |
perfosfamide results in decreased expression of MRE11A mRNA |
CTD |
PMID:11754170 |
|
NCBI chr 8:11,618,876...11,680,451
Ensembl chr 8:11,632,354...11,678,279
|
|
G |
Myo1b |
myosin Ib |
increases expression |
ISO |
perfosfamide results in increased expression of MYO1B mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 9:49,690,043...49,852,373
Ensembl chr 9:49,690,086...49,850,798
|
|
G |
Myog |
myogenin |
increases expression |
ISO |
perfosfamide results in increased expression of MYOG mRNA |
CTD |
PMID:19429390 |
|
NCBI chr13:45,745,455...45,748,044
Ensembl chr13:45,745,436...45,748,039
|
|
G |
Ndn |
necdin, MAGE family member |
increases expression |
ISO |
perfosfamide results in increased expression of NDN mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 1:115,849,168...115,850,767
Ensembl chr 1:115,849,105...115,850,767
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
decreases expression |
ISO |
perfosfamide results in decreased expression of ODC1 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Pea15 |
proliferation and apoptosis adaptor protein 15 |
decreases expression |
ISO |
perfosfamide results in decreased expression of PEA15 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr13:84,657,815...84,667,437
Ensembl chr13:84,654,870...84,667,499
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
increases expression |
ISO |
perfosfamide results in increased expression of PMAIP1 mRNA |
CTD |
PMID:17068108 |
|
NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429
|
|
G |
Pms1 |
PMS1 homolog 1, mismatch repair system component |
decreases expression |
EXP |
perfosfamide results in decreased expression of PMS1 mRNA |
CTD |
PMID:11754170 |
|
NCBI chr 9:48,229,403...48,340,237
Ensembl chr 9:48,253,410...48,340,237
|
|
G |
Pms2 |
PMS1 homolog 2, mismatch repair system component |
decreases expression |
EXP |
perfosfamide results in decreased expression of PMS2 mRNA |
CTD |
PMID:11754170 |
|
NCBI chr12:10,676,818...10,701,161
Ensembl chr12:10,676,764...10,701,066
|
|
G |
Polb |
DNA polymerase beta |
decreases expression |
EXP |
perfosfamide results in decreased expression of POLB mRNA |
CTD |
PMID:11754170 |
|
NCBI chr16:69,379,438...69,402,710
Ensembl chr16:69,379,400...69,404,812
|
|
G |
Pold1 |
DNA polymerase delta 1, catalytic subunit |
decreases expression |
ISO |
perfosfamide results in decreased expression of POLD1 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 1:95,025,462...95,041,559
Ensembl chr 1:95,025,499...95,036,465
|
|
G |
Rad21 |
RAD21 cohesin complex component |
decreases expression |
ISO |
perfosfamide results in decreased expression of RAD21 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 7:83,287,867...83,314,810
Ensembl chr 7:83,287,870...83,314,817
|
|
G |
Rad50 |
RAD50 double strand break repair protein |
decreases expression |
EXP |
perfosfamide results in decreased expression of RAD50 mRNA |
CTD |
PMID:11754170 |
|
NCBI chr10:37,809,353...37,861,309
Ensembl chr10:37,808,726...37,861,396
|
|
G |
Rad51 |
RAD51 recombinase |
decreases expression |
EXP |
perfosfamide results in decreased expression of RAD51 mRNA |
CTD |
PMID:11754170 |
|
NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035
|
|
G |
Sdf4 |
stromal cell derived factor 4 |
decreases expression |
ISO |
perfosfamide results in decreased expression of SDF4 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 5:166,586,581...166,606,661
Ensembl chr 5:166,586,390...166,604,521
|
|
G |
Sfrp2 |
secreted frizzled-related protein 2 |
decreases expression |
ISO |
perfosfamide results in decreased expression of SFRP2 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 2:169,089,517...169,097,064
Ensembl chr 2:169,089,517...169,097,063
|
|
G |
Slc30a4 |
solute carrier family 30 member 4 |
decreases expression |
ISO |
perfosfamide results in decreased expression of SLC30A4 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 3:109,753,270...109,775,306
Ensembl chr 3:109,753,273...109,775,306
|
|
G |
Smad1 |
SMAD family member 1 |
decreases expression |
ISO |
perfosfamide results in decreased expression of SMAD1 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr19:28,513,130...28,573,665
Ensembl chr19:28,513,131...28,573,651
|
|
G |
Tap1 |
transporter 1, ATP binding cassette subfamily B member |
affects response to substance |
ISO |
TAP1 protein affects the susceptibility to perfosfamide |
CTD |
PMID:18473730 |
|
NCBI chr20:4,656,262...4,666,634
Ensembl chr20:4,656,263...4,666,901
|
|
G |
Tcf12 |
transcription factor 12 |
increases expression |
ISO |
perfosfamide results in increased expression of TCF12 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 8:72,490,447...72,799,265
Ensembl chr 8:72,492,567...72,799,201
|
|
G |
Terc |
telomerase RNA component |
decreases expression |
ISO |
perfosfamide results in decreased expression of TERC mRNA |
CTD |
PMID:24571982 |
|
NCBI chr 2:112,815,654...112,816,041
|
|
G |
Tert |
telomerase reverse transcriptase |
decreases expression |
ISO |
perfosfamide results in decreased expression of TERT mRNA |
CTD |
PMID:24571982 |
|
NCBI chr 1:29,637,213...29,659,561
Ensembl chr 1:29,637,506...29,659,561
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
perfosfamide promotes the reaction [TNF results in increased activity of CASP3 protein] |
CTD |
PMID:16488414 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases expression |
ISO |
Acetylcysteine inhibits the reaction [perfosfamide results in increased expression of TP53] perfosfamide results in increased expression of and results in increased phosphorylation of and results in increased activity of TRP53 protein |
CTD |
PMID:17068108 PMID:18034189 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Trim27 |
tripartite motif-containing 27 |
decreases expression |
ISO |
perfosfamide results in decreased expression of TRIM27 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr17:43,538,282...43,550,633
Ensembl chr17:43,538,285...43,550,643
|
|
G |
Ttf1 |
transcription termination factor 1 |
decreases expression |
ISO |
perfosfamide results in decreased expression of TTF1 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 3:12,384,626...12,409,257
Ensembl chr 3:12,384,655...12,409,257
|
|
G |
Ubb |
ubiquitin B |
decreases expression |
ISO |
perfosfamide results in decreased expression of UBB mRNA |
CTD |
PMID:19429390 |
|
NCBI chr10:47,247,630...47,249,335
Ensembl chr10:47,245,637...47,249,333
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression |
ISO |
perfosfamide results in increased expression of VEGFA mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vim |
vimentin |
decreases expression |
ISO |
perfosfamide results in decreased expression of VIM mRNA |
CTD |
PMID:19429390 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Wnt11 |
Wnt family member 11 |
increases expression |
ISO |
perfosfamide results in increased expression of WNT11 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 1:153,134,503...153,154,294
Ensembl chr 1:153,138,197...153,154,294
|
|
G |
Xrcc1 |
X-ray repair cross complementing 1 |
decreases expression |
EXP |
perfosfamide results in decreased expression of XRCC1 mRNA |
CTD |
PMID:11754170 |
|
NCBI chr 1:80,140,495...80,168,705
Ensembl chr 1:80,141,207...80,168,701
|
|
G |
Xrcc5 |
X-ray repair cross complementing 5 |
decreases expression |
EXP |
perfosfamide results in decreased expression of XRCC5 mRNA |
CTD |
PMID:11754170 |
|
NCBI chr 9:73,955,216...74,044,020
Ensembl chr 9:73,955,216...74,044,018
|
|
G |
Ywhaz |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta |
decreases expression |
ISO |
perfosfamide results in decreased expression of YWHAZ mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 7:67,941,353...67,963,651
Ensembl chr 7:67,940,017...67,963,668
|
|
|
G |
Ephx3 |
epoxide hydrolase 3 |
multiple interactions |
ISO |
[EPHX3 gene mutant form results in decreased hydrolysis of Epoxy Compounds] results in decreased abundance of [9,10,13-trihydroxy-11-octadecenoic acid binds to Ceramides]; [EPHX3 gene mutant form results in decreased hydrolysis of Epoxy Compounds] which results in decreased chemical synthesis of 9,10,13-trihydroxy-11-octadecenoic acid |
CTD |
PMID:33334892 |
|
NCBI chr 7:11,206,812...11,212,122
Ensembl chr 7:11,206,812...11,212,122
|
|
|
G |
Cat |
catalase |
decreases activity increases activity multiple interactions |
ISO EXP |
cumene hydroperoxide results in decreased activity of CAT protein cumene hydroperoxide results in increased activity of CAT protein Iron promotes the reaction [cumene hydroperoxide results in decreased activity of CAT protein]; Iron-Dextran Complex promotes the reaction [cumene hydroperoxide results in decreased activity of CAT protein] |
CTD |
PMID:12065085 PMID:12423650 PMID:16928893 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
affects oxidation |
EXP |
CYP2B1 protein affects the oxidation of cumene hydroperoxide |
CTD |
PMID:17478480 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
affects oxidation |
EXP |
CYP2B6 protein affects the oxidation of cumene hydroperoxide |
CTD |
PMID:17478480 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
affects oxidation |
ISO |
CYP2C19 protein affects the oxidation of cumene hydroperoxide |
CTD |
PMID:17478480 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
affects oxidation |
ISO |
CYP2C8 protein affects the oxidation of cumene hydroperoxide |
CTD |
PMID:17478480 |
|
|
|
G |
Cyp2d1 |
cytochrome P450, family 2, subfamily d, polypeptide 1 |
affects oxidation |
EXP |
CYP2D1 protein affects the oxidation of cumene hydroperoxide |
CTD |
PMID:17478480 |
|
NCBI chr 7:113,908,950...113,913,420
Ensembl chr 7:113,908,947...113,922,084
|
|
G |
Cyp2s1 |
cytochrome P450, family 2, subfamily s, polypeptide 1 |
multiple interactions |
ISO |
[[CYP2S1 protein co-treated with cumene hydroperoxide] results in increased oxidation of benzo(a)pyrene 7,8-dihydrodiol] which results in increased abundance of benzo(a)pyrene-7,8,9,10-tetrol; [[CYP2S1 protein co-treated with cumene hydroperoxide] results in increased oxidation of Benzo(a)pyrene] which results in increased abundance of benzo(a)pyrene-1,6-quinone; [[CYP2S1 protein co-treated with cumene hydroperoxide] results in increased oxidation of Benzo(a)pyrene] which results in increased abundance of benzo(a)pyrene-3,6-quinone; [[CYP2S1 protein co-treated with cumene hydroperoxide] results in increased oxidation of Benzo(a)pyrene] which results in increased abundance of benzo(a)pyrene-6,12-quinone; [CYP2S1 protein co-treated with cumene hydroperoxide] results in increased oxidation of 9,10-dihydrobenzo(a)pyrene; [CYP2S1 protein co-treated with cumene hydroperoxide] results in increased oxidation of 9,10-Dimethyl-1,2-benzanthracene; [CYP2S1 protein co-treated with cumene hydroperoxide] results in increased oxidation of Aflatoxin B1; [CYP2S1 protein co-treated with cumene hydroperoxide] results in increased oxidation of Benzo(a)pyrene; [CYP2S1 protein co-treated with cumene hydroperoxide] results in increased oxidation of benzo(a)pyrene 7,8-dihydrodiol; [CYP2S1 protein co-treated with cumene hydroperoxide] results in increased oxidation of Tretinoin |
CTD |
PMID:19713358 |
|
NCBI chr 1:81,309,948...81,325,303
Ensembl chr 1:81,310,451...81,325,303
|
|
G |
Eef2 |
eukaryotic translation elongation factor 2 |
multiple interactions decreases expression |
EXP |
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [cumene hydroperoxide results in decreased expression of EEF2 protein]; Vitamin E analog inhibits the reaction [cumene hydroperoxide results in decreased expression of EEF2 protein] cumene hydroperoxide results in decreased expression of EEF2; cumene hydroperoxide results in decreased expression of EEF2 protein |
CTD |
PMID:16469450 PMID:17510559 PMID:19447174 |
|
NCBI chr 7:8,533,248...8,538,518
Ensembl chr 7:8,533,116...8,559,183
|
|
G |
Fgfr2 |
fibroblast growth factor receptor 2 |
multiple interactions |
ISO |
cumene hydroperoxide results in increased phosphorylation of and results in increased activity of FGFR2 protein |
CTD |
PMID:12717419 |
|
NCBI chr 1:184,745,418...184,850,655
Ensembl chr 1:184,745,420...184,850,626
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
increases activity |
EXP |
cumene hydroperoxide results in increased activity of G6PD protein |
CTD |
PMID:16928893 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
increases expression |
ISO |
cumene hydroperoxide results in increased expression of GAPDH protein |
CTD |
PMID:11295360 |
|
NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression |
ISO |
cumene hydroperoxide results in increased expression of GCLC mRNA |
CTD |
PMID:30547568 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression |
ISO |
cumene hydroperoxide results in increased expression of GCLM mRNA |
CTD |
PMID:30547568 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
decreases response to substance increases metabolic processing increases reduction |
ISO |
GPX1 protein results in decreased susceptibility to cumene hydroperoxide GPX1 protein results in increased metabolism of cumene hydroperoxide GPX1 protein results in increased reduction of cumene hydroperoxide |
CTD |
PMID:1740415 PMID:1939125 PMID:8428933 PMID:9126277 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
increases reduction |
ISO |
GPX2 protein results in increased reduction of cumene hydroperoxide |
CTD |
PMID:8428933 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
decreases response to substance |
ISO |
GPX4 results in decreased susceptibility to cumene hydroperoxide |
CTD |
PMID:18206984 |
|
NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982
|
|
G |
Gsr |
glutathione-disulfide reductase |
decreases activity |
EXP |
cumene hydroperoxide results in decreased activity of GSR protein |
CTD |
PMID:16928893 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
increases metabolic processing |
ISO |
GSTA1 protein results in increased metabolism of cumene hydroperoxide |
CTD |
PMID:1985777 |
|
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
decreases metabolic processing increases metabolic processing |
ISO |
GSTA2 protein polymorphism results in decreased metabolism of cumene hydroperoxide GSTA2 protein results in increased metabolism of cumene hydroperoxide |
CTD |
PMID:3138230 PMID:15077012 PMID:15128049 |
|
NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798
|
|
G |
Gsta3 |
glutathione S-transferase alpha 3 |
decreases response to substance affects metabolic processing |
EXP |
GSTA3 protein results in decreased susceptibility to cumene hydroperoxide GSTA3 protein affects the metabolism of cumene hydroperoxide |
CTD |
PMID:1740415 PMID:2768223 |
|
NCBI chr 9:23,658,574...23,684,240
Ensembl chr 9:23,658,574...23,684,240
|
|
G |
Gstm5 |
glutathione S-transferase, mu 5 |
decreases metabolic processing increases metabolic processing |
ISO |
GSTM3 protein polymorphism results in decreased metabolism of cumene hydroperoxide GSTM3 protein polymorphism results in increased metabolism of cumene hydroperoxide |
CTD |
PMID:15247628 |
|
NCBI chr 2:195,531,599...195,534,562
Ensembl chr 2:195,531,495...195,534,553
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
increases metabolic processing |
ISO |
GSTP1 protein results in increased metabolism of cumene hydroperoxide |
CTD |
PMID:2747627 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gstt1 |
glutathione S-transferase theta 1 |
affects oxidation affects metabolic processing |
ISO |
GSTT1 protein affects the oxidation of cumene hydroperoxide GSTT1 protein affects the metabolism of cumene hydroperoxide |
CTD |
PMID:9854036 PMID:19664997 |
|
NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585
|
|
G |
Gstt2 |
glutathione S-transferase theta 2 |
affects metabolic processing |
EXP |
GSTT2 protein affects the metabolism of cumene hydroperoxide |
CTD |
PMID:2114406 |
|
NCBI chr20:12,819,617...12,823,288
Ensembl chr20:12,819,170...12,823,288
|
|
G |
Gstz1 |
glutathione S-transferase zeta 1 |
affects metabolic processing |
ISO |
GSTZ1 protein affects the metabolism of cumene hydroperoxide |
CTD |
PMID:9396740 |
|
NCBI chr 6:106,794,594...106,805,284
Ensembl chr 6:106,794,074...106,805,284
|
|
G |
Gusb |
glucuronidase, beta |
multiple interactions decreases uptake increases secretion |
ISO |
alpha-Tocopherol inhibits the reaction [cumene hydroperoxide results in decreased uptake of GUSB protein]; alpha-Tocopherol inhibits the reaction [cumene hydroperoxide results in increased secretion of GUSB protein] |
CTD |
PMID:19135433 |
|
NCBI chr12:26,701,188...26,714,718
Ensembl chr12:26,697,951...26,726,905
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
cumene hydroperoxide results in increased expression of HMOX1 mRNA |
CTD |
PMID:30547568 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
increases expression |
ISO |
cumene hydroperoxide results in increased expression of HSPB1 protein |
CTD |
PMID:11295360 |
|
NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
|
|
G |
Idh1 |
isocitrate dehydrogenase (NADP(+)) 1 |
increases activity |
EXP |
cumene hydroperoxide results in increased activity of IDH1 protein |
CTD |
PMID:16928893 |
|
NCBI chr 9:66,534,146...66,563,703
Ensembl chr 9:66,534,146...66,563,708
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases secretion |
ISO |
alpha-Tocopherol inhibits the reaction [cumene hydroperoxide results in increased secretion of IL1B protein] |
CTD |
PMID:19135433 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
ISO |
[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to cumene hydroperoxide; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to cumene hydroperoxide] |
CTD |
PMID:19608619 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Mb |
myoglobin |
affects metabolic processing |
ISO |
MB protein mutant form affects the metabolism of cumene hydroperoxide |
CTD |
PMID:8855949 |
|
NCBI chr 7:108,759,903...108,767,134
Ensembl chr 7:108,759,904...108,767,383
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
decreases response to substance |
EXP |
MGST1 results in decreased susceptibility to cumene hydroperoxide |
CTD |
PMID:17306223 |
|
NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
[9,10-Dimethyl-1,2-benzanthracene co-treated with cumene hydroperoxide] results in increased activity of MPO protein |
CTD |
PMID:14972014 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases response to substance affects response to substance multiple interactions |
ISO |
NFE2L2 gene mutant form results in increased susceptibility to cumene hydroperoxide [NFE2L2 affects the susceptibility to sulforaphane] which affects the susceptibility to cumene hydroperoxide Buthionine Sulfoximine inhibits the reaction [NFE2L2 protein promotes the reaction [sulforaphane results in decreased susceptibility to cumene hydroperoxide]]; NFE2L2 protein promotes the reaction [sulforaphane results in decreased susceptibility to cumene hydroperoxide] [KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to cumene hydroperoxide; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to cumene hydroperoxide] |
CTD |
PMID:19303893 PMID:19608619 PMID:20932822 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression |
ISO |
alpha-Tocopherol inhibits the reaction [cumene hydroperoxide results in increased expression of NOS2 protein] |
CTD |
PMID:19135433 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
ISO |
cumene hydroperoxide results in increased expression of NQO1 mRNA |
CTD |
PMID:30547568 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
increases activity multiple interactions |
ISO |
cumene hydroperoxide results in increased activity of ODC1 protein Iron promotes the reaction [cumene hydroperoxide results in increased activity of ODC1 protein]; Iron-Dextran Complex promotes the reaction [cumene hydroperoxide results in increased activity of ODC1 protein] |
CTD |
PMID:12065085 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Ppia |
peptidylprolyl isomerase A |
decreases response to substance |
EXP |
PPIA protein results in decreased susceptibility to cumene hydroperoxide |
CTD |
PMID:17011206 |
|
NCBI chr14:81,279,292...81,282,960
Ensembl chr14:81,275,091...81,299,601
|
|
G |
Prdx1 |
peroxiredoxin 1 |
increases expression |
ISO |
cumene hydroperoxide results in increased expression of PRDX1 protein |
CTD |
PMID:11295360 |
|
NCBI chr 5:130,147,258...130,162,856
Ensembl chr 5:130,147,204...130,162,856
|
|
G |
Prdx2 |
peroxiredoxin 2 |
increases expression |
ISO |
cumene hydroperoxide results in increased expression of PRDX2 protein |
CTD |
PMID:11295360 |
|
NCBI chr19:23,180,927...23,186,217
Ensembl chr19:23,180,930...23,186,194
|
|
G |
Prdx6 |
peroxiredoxin 6 |
increases expression |
ISO |
cumene hydroperoxide results in increased expression of PRDX6 protein |
CTD |
PMID:11295360 |
|
NCBI chr13:73,528,746...73,539,295
Ensembl chr13:73,528,210...73,539,355
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression multiple interactions |
ISO |
cumene hydroperoxide results in increased expression of PTGS2 protein [cumene hydroperoxide results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [cumene hydroperoxide results in increased expression of PTGS2 protein] |
CTD |
PMID:14972014 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Sord |
sorbitol dehydrogenase |
increases activity |
EXP |
cumene hydroperoxide results in increased activity of SORD protein |
CTD |
PMID:16928893 |
|
NCBI chr 3:109,184,697...109,216,133
Ensembl chr 3:109,184,676...109,216,133
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression |
ISO |
cumene hydroperoxide results in increased expression of TGFB1 mRNA |
CTD |
PMID:8148055 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases secretion |
ISO |
alpha-Tocopherol inhibits the reaction [cumene hydroperoxide results in increased secretion of TNF protein] |
CTD |
PMID:19135433 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Agt |
angiotensinogen |
multiple interactions increases lipidation |
ISO |
Ascorbic Acid promotes the reaction [linoleic acid hydroperoxide results in increased lipidation of AGT protein modified form] |
CTD |
PMID:26111765 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Cygb |
cytoglobin |
increases metabolic processing |
EXP |
CYGB protein results in increased metabolism of linoleic acid hydroperoxide |
CTD |
PMID:11320098 |
|
NCBI chr10:101,877,675...101,887,442
Ensembl chr10:101,877,676...101,887,442
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
increases reduction |
ISO |
GPX1 protein results in increased reduction of linoleic acid hydroperoxide |
CTD |
PMID:8428933 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
increases reduction |
ISO |
GPX2 protein results in increased reduction of linoleic acid hydroperoxide |
CTD |
PMID:8428933 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ABCA1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions decreases expression affects localization |
EXP ISO |
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [tert-Butylhydroperoxide affects the localization of ABCB11 protein]; Bilirubin analog inhibits the reaction [tert-Butylhydroperoxide affects the localization of and results in decreased activity of ABCB11 protein]; Bucladesine inhibits the reaction [tert-Butylhydroperoxide affects the localization of ABCB11 protein]; tert-Butylhydroperoxide affects the localization of and results in decreased activity of ABCB11 protein tert-Butylhydroperoxide results in decreased expression of ABCB11 mRNA |
CTD |
PMID:16452108 PMID:24306262 PMID:34767876 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ABCB1A mRNA |
CTD |
PMID:14729362 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
decreases expression affects localization multiple interactions |
ISO EXP |
tert-Butylhydroperoxide results in decreased expression of ABCC2 mRNA tert-Butylhydroperoxide affects the localization of ABCC2 protein Acetylcysteine inhibits the reaction [tert-Butylhydroperoxide affects the localization of ABCC2 protein]; Bilirubin analog inhibits the reaction [tert-Butylhydroperoxide affects the localization of and results in decreased activity of ABCC2 protein]; Go 6976 inhibits the reaction [tert-Butylhydroperoxide affects the localization of ABCC2 protein]; tert-Butylhydroperoxide affects the localization of and results in decreased activity of ABCC2 protein |
CTD |
PMID:22956110 PMID:24306262 PMID:34303734 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcd1 |
ATP binding cassette subfamily D member 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ABCD1 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr X:151,428,334...151,450,115
Ensembl chr X:151,428,578...151,450,115
|
|
G |
Abhd17a |
abhydrolase domain containing 17A, depalmitoylase |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ABHD17A mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:9,124,332...9,132,762
Ensembl chr 7:9,124,332...9,130,762
|
|
G |
Ablim1 |
actin-binding LIM protein 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ABLIM1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:256,083,747...256,372,075
Ensembl chr 1:256,084,297...256,371,969
|
|
G |
Abr |
ABR activator of RhoGEF and GTPase |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ABR mRNA |
CTD |
PMID:15003993 |
|
NCBI chr10:61,262,516...61,461,331
Ensembl chr10:61,262,516...61,461,505
|
|
G |
Acads |
acyl-CoA dehydrogenase short chain |
increases expression multiple interactions decreases expression |
ISO EXP |
tert-Butylhydroperoxide results in increased expression of ACADS mRNA acadesine inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of ACADS mRNA]; acadesine inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of and results in decreased activity of ACADS protein]; Fenofibrate inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of ACADS mRNA]; Fenofibrate inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of and results in decreased activity of ACADS protein]; tert-Butylhydroperoxide results in decreased expression of and results in decreased activity of ACADS protein |
CTD |
PMID:15003993 PMID:26989860 |
|
NCBI chr12:41,493,650...41,502,897
Ensembl chr12:41,493,626...41,502,898
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions increases secretion increases expression |
EXP |
Benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(N,N-dimethyl-N-2-propenyl-), Dibromide inhibits the reaction [tert-Butylhydroperoxide results in increased secretion of ACHE protein] tert-Butylhydroperoxide results in increased expression of ACHE mRNA alternative form |
CTD |
PMID:16903848 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Ackr3 |
atypical chemokine receptor 3 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ACKR3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 9:90,799,682...90,811,246
Ensembl chr 9:90,799,686...90,811,237
|
|
G |
Aco1 |
aconitase 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ACO1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 5:55,259,841...55,315,872
Ensembl chr 5:55,259,827...55,316,391
|
|
G |
Acot1 |
acyl-CoA thioesterase 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ACOT1 mRNA |
CTD |
PMID:14729362 |
|
NCBI chr 6:103,636,173...103,644,167
Ensembl chr 6:103,636,041...103,644,163
|
|
G |
Acot7 |
acyl-CoA thioesterase 7 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ACOT7 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 5:162,686,562...162,779,309
Ensembl chr 5:162,684,645...162,779,309
|
|
G |
Acsl3 |
acyl-CoA synthetase long-chain family member 3 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ACSL3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 9:80,115,164...80,164,636
Ensembl chr 9:80,115,112...80,164,627
|
|
G |
Actb |
actin, beta |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ACTB mRNA |
CTD |
PMID:12419474 |
|
NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877
|
|
G |
Actg2 |
actin gamma 2, smooth muscle |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ACTG2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:116,021,832...116,046,475
Ensembl chr 4:116,021,832...116,046,465
|
|
G |
Actn1 |
actinin, alpha 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ACTN1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 6:98,998,553...99,093,334
Ensembl chr 6:98,998,556...99,093,251
|
|
G |
Actr3 |
actin related protein 3 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ACTR3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr13:36,800,739...36,843,837
Ensembl chr13:36,800,093...36,844,124
|
|
G |
Actr3b |
actin related protein 3B |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ACTR3B mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:9,261,631...9,355,496
Ensembl chr 4:9,262,233...9,355,441
|
|
G |
Acy3 |
aminoacylase 3 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ACY3 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 1:201,279,751...201,285,803
Ensembl chr 1:201,279,851...201,283,175
|
|
G |
Acyp1 |
acylphosphatase 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ACYP1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 6:104,919,162...104,932,348
Ensembl chr 6:104,919,162...104,932,387
|
|
G |
Adam19 |
ADAM metallopeptidase domain 19 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ADAM19 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:30,491,362...30,583,115
Ensembl chr10:30,491,405...30,583,105
|
|
G |
Adam8 |
ADAM metallopeptidase domain 8 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ADAM8 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 1:194,776,559...194,789,330
Ensembl chr 1:194,770,060...194,788,801
|
|
G |
Adam9 |
ADAM metallopeptidase domain 9 |
multiple interactions affects expression increases expression |
ISO |
[rosiglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of ADAM9 mRNA; pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ADAM9 mRNA]; rosiglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ADAM9 mRNA]; troglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ADAM9 mRNA] tert-Butylhydroperoxide affects the expression of ADAM9 mRNA |
CTD |
PMID:20847119 PMID:23410634 |
|
NCBI chr16:67,022,538...67,101,647
Ensembl chr16:67,022,655...67,100,917
|
|
G |
Adar |
adenosine deaminase, RNA-specific |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ADAR mRNA |
CTD |
PMID:14729362 PMID:15003993 |
|
NCBI chr 2:175,138,391...175,178,280
Ensembl chr 2:175,138,403...175,178,282
|
|
G |
Adat1 |
adenosine deaminase, tRNA-specific 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ADAT1 mRNA |
CTD |
PMID:15963989 |
|
NCBI chr19:39,918,083...39,956,886
Ensembl chr19:39,918,227...39,956,883
|
|
G |
Adcy3 |
adenylate cyclase 3 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ADCY3 mRNA |
CTD |
PMID:12414654 |
|
NCBI chr 6:27,100,089...27,203,686
Ensembl chr 6:27,124,828...27,203,686
|
|
G |
Adcy9 |
adenylate cyclase 9 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ADCY9 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:11,138,966...11,262,067
Ensembl chr10:11,139,446...11,262,066
|
|
G |
Add2 |
adducin 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ADD2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:118,444,594...118,538,505
Ensembl chr 4:118,497,416...118,538,505
|
|
G |
Add3 |
adducin 3 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ADD3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:252,147,341...252,255,126
Ensembl chr 1:252,147,386...252,255,124
|
|
G |
Adgrg6 |
adhesion G protein-coupled receptor G6 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ADGRG6 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:8,812,889...8,954,239
Ensembl chr 1:8,812,904...8,954,123
|
|
G |
Adh7 |
alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ADH7 mRNA |
CTD |
PMID:14729362 PMID:15336504 |
|
NCBI chr 2:226,748,724...226,763,183
Ensembl chr 2:226,741,788...226,763,182
|
|
G |
Adipor2 |
adiponectin receptor 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ADIPOR2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:152,524,604...152,588,848
Ensembl chr 4:152,524,623...152,559,355
|
|
G |
Adm |
adrenomedullin |
multiple interactions increases expression |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of ADM mRNA; [rosiglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of ADM mRNA; [troglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of ADM mRNA; rosiglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ADM mRNA]; troglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ADM mRNA] |
CTD |
PMID:14729362 PMID:15003993 PMID:15336504 PMID:20847119 PMID:29432895 |
|
NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654
|
|
G |
Adora1 |
adenosine A1 receptor |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ADORA1 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr13:45,658,872...45,695,821
Ensembl chr13:45,658,872...45,695,801
|
|
G |
Adora2b |
adenosine A2B receptor |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ADORA2B mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:46,940,394...46,956,772
Ensembl chr10:46,940,384...46,956,772
|
|
G |
Agk |
acylglycerol kinase |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of AGK mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:69,114,850...69,193,989
Ensembl chr 4:69,114,269...69,193,934
|
|
G |
Ago2 |
argonaute RISC catalytic component 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of AGO2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:105,018,202...105,105,118
Ensembl chr 7:105,029,120...105,104,974
|
|
G |
Agpat1 |
1-acylglycerol-3-phosphate O-acyltransferase 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of AGPAT1 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr20:4,135,955...4,144,880
Ensembl chr20:4,135,957...4,145,278
|
|
G |
Ahsa1 |
activator of Hsp90 ATPase activity 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of AHSA1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 6:106,913,296...106,921,347
Ensembl chr 6:106,913,530...106,921,345
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
multiple interactions increases expression |
ISO |
resveratrol inhibits the reaction [tert-Butylhydroperoxide results in increased expression of AIFM1 protein] |
CTD |
PMID:25522270 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Aip |
aryl-hydrocarbon receptor-interacting protein |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of AIP mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:201,408,002...201,419,220
Ensembl chr 1:201,407,288...201,419,122
|
|
G |
Ajuba |
ajuba LIM protein |
multiple interactions decreases expression |
ISO |
[Pioglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of AJUBA mRNA; [Rosiglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of AJUBA mRNA; [Troglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of AJUBA mRNA; Troglitazone inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of AJUBA mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr15:28,019,775...28,031,537
Ensembl chr15:28,019,778...28,030,021
|
|
G |
Ak2 |
adenylate kinase 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of AK2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 5:141,308,650...141,364,633
Ensembl chr 5:141,346,063...141,364,632
|
|
G |
Ak4 |
adenylate kinase 4 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of AK4 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 5:116,039,222...116,099,064
Ensembl chr 5:116,039,616...116,098,618
|
|
G |
Akap12 |
A-kinase anchoring protein 12 |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of AKAP12 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr 1:40,730,123...40,819,863
Ensembl chr 1:40,730,123...40,819,886
|
|
G |
Akap9 |
A-kinase anchoring protein 9 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of AKAP9 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:30,056,738...30,192,716
Ensembl chr 4:30,056,738...30,192,606
|
|
G |
Akr1b10 |
aldo-keto reductase family 1 member B10 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of AKR1B10 mRNA |
CTD |
PMID:23410634 PMID:34767876 |
|
NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of AKR1C1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326
|
|
G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of AKR1C2 mRNA |
CTD |
PMID:12414654 PMID:15336504 PMID:23410634 |
|
NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation multiple interactions |
ISO |
tert-Butylhydroperoxide results in decreased phosphorylation of AKT1 protein 3,4-dihydroxyphenyllactic acid inhibits the reaction [tert-Butylhydroperoxide results in decreased phosphorylation of AKT1 protein]; [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of AKT1 mRNA; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of AKT1 mRNA] |
CTD |
PMID:29128606 PMID:35690295 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
decreases expression increases methylation |
ISO |
tert-Butylhydroperoxide results in decreased expression of AKT2 mRNA tert-Butylhydroperoxide results in increased methylation of AKT2 gene |
CTD |
PMID:27509014 |
|
NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817
|
|
G |
Alad |
aminolevulinate dehydratase |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ALAD mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 5:75,961,993...75,972,334
Ensembl chr 5:75,961,993...75,972,474
|
|
G |
Alas1 |
5'-aminolevulinate synthase 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ALAS1 protein |
CTD |
PMID:21659532 |
|
NCBI chr 8:106,876,514...106,889,917
Ensembl chr 8:106,876,514...106,889,917
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
decreases expression affects expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ALDH1A1 mRNA tert-Butylhydroperoxide affects the expression of ALDH1A1 mRNA |
CTD |
PMID:15336504 PMID:23410634 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldh1a3 |
aldehyde dehydrogenase 1 family, member A3 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ALDH1A3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:119,982,272...120,017,416
Ensembl chr 1:119,982,277...120,017,436
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
increases expression decreases response to substance |
ISO |
tert-Butylhydroperoxide results in increased expression of ALDH2 mRNA ALDH2 protein results in decreased susceptibility to tert-Butylhydroperoxide |
CTD |
PMID:14729362 PMID:15003993 PMID:15336504 |
|
NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521
|
|
G |
Aldh3a2 |
aldehyde dehydrogenase 3 family, member A2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ALDH3A2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:45,928,313...45,949,366
Ensembl chr10:45,908,524...45,949,281
|
|
G |
Aldh4a1 |
aldehyde dehydrogenase 4 family, member A1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ALDH4A1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 5:151,880,002...151,905,491
Ensembl chr 5:151,830,701...151,925,345
|
|
G |
Aldh6a1 |
aldehyde dehydrogenase 6 family, member A1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ALDH6A1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 6:104,077,975...104,098,636
Ensembl chr 6:104,077,979...104,098,656
|
|
G |
Aldh7a1 |
aldehyde dehydrogenase 7 family, member A1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ALDH7A1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr18:50,003,242...50,042,193
Ensembl chr18:50,009,934...50,042,193
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ALDOA mRNA |
CTD |
PMID:15003993 |
|
NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ALOX5 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Amd1 |
adenosylmethionine decarboxylase 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of AMD1 mRNA |
CTD |
PMID:27509014 |
|
NCBI chr20:43,695,783...43,711,476
Ensembl chr20:43,697,237...43,711,476
|
|
G |
Amigo2 |
adhesion molecule with Ig like domain 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of AMIGO2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:128,391,493...128,394,589
Ensembl chr 7:128,390,412...128,394,695
|
|
G |
Amotl2 |
angiomotin like 2 |
multiple interactions decreases expression |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of AMOTL2 mRNA; [rosiglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of AMOTL2 mRNA; [troglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of AMOTL2 mRNA; tert-Butylhydroperoxide promotes the reaction [PPARG protein binds to AMOTL2 promoter]; troglitazone inhibits the reaction [tert-Butylhydroperoxide promotes the reaction [PPARG protein binds to AMOTL2 promoter]]; troglitazone inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of AMOTL2 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr 8:103,303,368...103,319,161
Ensembl chr 8:103,302,992...103,318,910
|
|
G |
Ampd3 |
adenosine monophosphate deaminase 3 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of AMPD3 mRNA |
CTD |
PMID:15003993 PMID:15336504 |
|
NCBI chr 1:164,884,823...164,929,899
Ensembl chr 1:164,885,320...164,929,887
|
|
G |
Amph |
amphiphysin |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of AMPH mRNA |
CTD |
PMID:12419474 PMID:15336504 |
|
NCBI chr17:45,739,385...45,982,905
Ensembl chr17:45,739,395...45,983,315
|
|
G |
Anapc5 |
anaphase-promoting complex subunit 5 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ANAPC5 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr12:33,748,709...33,781,709
Ensembl chr12:33,748,735...33,781,781
|
|
G |
Angptl2 |
angiopoietin-like 2 |
multiple interactions increases expression |
ISO |
[Pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of ANGPTL2 mRNA; [Rosiglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of ANGPTL2 mRNA; Pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ANGPTL2 mRNA]; Troglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ANGPTL2 mRNA] |
CTD |
PMID:15003993 PMID:20847119 |
|
NCBI chr 3:16,517,185...16,547,024
Ensembl chr 3:16,517,420...16,548,178
|
|
G |
Angptl7 |
angiopoietin like 7 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ANGPTL7 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 5:158,932,096...158,937,281
Ensembl chr 5:158,932,794...158,937,324
|
|
G |
Ankmy2 |
ankyrin repeat and MYND domain containing 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ANKMY2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 6:52,888,959...52,930,343
Ensembl chr 6:52,888,963...52,930,394
|
|
G |
Ankra2 |
ankyrin repeat family A member 2 |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of ANKRA2 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr 2:29,612,867...29,623,748
Ensembl chr 2:29,612,925...29,623,730
|
|
G |
Ankrd10 |
ankyrin repeat domain 10 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ANKRD10 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr16:77,866,489...77,889,745
Ensembl chr16:77,864,261...77,889,745
|
|
G |
Ankrd2 |
ankyrin repeat domain 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ANKRD2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:240,847,111...240,856,563
Ensembl chr 1:240,847,072...240,856,566
|
|
G |
Ankrd37 |
ankyrin repeat domain 37 |
multiple interactions increases expression |
ISO |
[Pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of ANKRD37 mRNA; [Rosiglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of ANKRD37 mRNA; [Troglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of ANKRD37 mRNA; Pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ANKRD37 mRNA]; Rosiglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ANKRD37 mRNA]; Troglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ANKRD37 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr16:46,268,933...46,271,971
Ensembl chr16:46,268,443...46,271,963
|
|
G |
Ankrd6 |
ankyrin repeat domain 6 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ANKRD6 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 5:47,197,981...47,343,183
Ensembl chr 5:47,202,873...47,343,090
|
|
G |
Anp32a |
acidic nuclear phosphoprotein 32 family member A |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ANP32A mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 8:62,829,099...62,865,443
Ensembl chr 8:62,827,456...62,865,443
|
|
G |
Anpep |
alanyl aminopeptidase, membrane |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ANPEP mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:133,767,332...133,810,137
Ensembl chr 1:133,767,332...133,785,789
|
|
G |
Anxa4 |
annexin A4 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ANXA4 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:119,184,378...119,241,183
Ensembl chr 4:119,184,374...119,241,161
|
|
G |
Anxa8 |
annexin A8 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ANXA8 mRNA |
CTD |
PMID:14729362 PMID:15003993 |
|
NCBI chr16:9,397,144...9,412,072
Ensembl chr16:9,397,113...9,412,043
|
|
G |
Aox1 |
aldehyde oxidase 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of AOX1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 9:59,579,621...59,658,772
Ensembl chr 9:59,579,649...59,658,770
|
|
G |
Ap3b1 |
adaptor related protein complex 3 subunit beta 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of AP3B1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 2:25,600,069...25,800,937
Ensembl chr 2:25,600,040...25,800,935
|
|
G |
Ap3d1 |
adaptor related protein complex 3 subunit delta 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of AP3D1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:8,970,249...9,005,651
Ensembl chr 7:8,970,291...9,005,643
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
increases expression multiple interactions |
ISO EXP |
tert-Butylhydroperoxide results in increased expression of APAF1 protein [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of APAF1 mRNA; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of APAF1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of APAF1 mRNA] Acetylcysteine inhibits the reaction [tert-Butylhydroperoxide results in increased expression of APAF1 protein] |
CTD |
PMID:15877105 PMID:17419000 PMID:35690295 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
Aplp2 |
amyloid beta precursor like protein 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of APLP2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 8:29,599,230...29,662,311
Ensembl chr 8:29,599,230...29,661,855
|
|
G |
Apoa5 |
apolipoprotein A5 |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of APOA5 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr 8:46,561,180...46,563,818
Ensembl chr 8:46,561,229...46,563,816
|
|
G |
Apoe |
apolipoprotein E |
increases expression affects localization |
ISO EXP |
tert-Butylhydroperoxide results in increased expression of APOE mRNA tert-Butylhydroperoxide affects the localization of APOE protein |
CTD |
PMID:15336504 PMID:19720132 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Apold1 |
apolipoprotein L domain containing 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of APOLD1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:167,768,437...167,825,706
Ensembl chr 4:167,818,271...167,825,706
|
|
G |
App |
amyloid beta precursor protein |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of APP mRNA |
CTD |
PMID:12419474 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Appl1 |
adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of APPL1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr16:2,118,503...2,166,741
Ensembl chr16:2,121,255...2,166,692
|
|
G |
Appl2 |
adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of APPL2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:20,135,248...20,184,757
Ensembl chr 7:20,135,375...20,184,754
|
|
G |
Aqp1 |
aquaporin 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of AQP1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:84,482,512...84,494,690
Ensembl chr 4:84,482,512...84,494,690
|
|
G |
Aqp4 |
aquaporin 4 |
multiple interactions |
EXP |
tert-Butylhydroperoxide results in increased expression of and affects the localization of AQP4 protein |
CTD |
PMID:20648640 |
|
NCBI chr18:6,507,903...6,524,558
Ensembl chr18:6,507,903...6,524,856
|
|
G |
Aqr |
aquarius intron-binding spliceosomal factor |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of AQR mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:100,874,987...100,945,026
Ensembl chr 3:100,874,987...100,945,044
|
|
G |
Areg |
amphiregulin |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of AREG mRNA |
CTD |
PMID:12414654 |
|
NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535
|
|
G |
Arf6 |
ARF GTPase 6 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ARF6 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 6:87,853,742...87,854,890
Ensembl chr 6:87,840,142...87,874,114
|
|
G |
Arg2 |
arginase 2 |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of ARG2 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr 6:97,936,002...97,961,379
Ensembl chr 6:97,936,002...97,961,378
|
|
G |
Arhgdia |
Rho GDP dissociation inhibitor alpha |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ARHGDIA mRNA |
CTD |
PMID:12419474 |
|
NCBI chr10:105,854,526...105,858,020
Ensembl chr10:105,854,533...105,858,023
|
|
G |
Arhgef10 |
Rho guanine nucleotide exchange factor 10 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ARHGEF10 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr16:74,647,147...74,738,784
Ensembl chr16:74,647,153...74,738,173
|
|
G |
Arhgef7 |
Rho guanine nucleotide exchange factor 7 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ARHGEF7 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr16:77,671,021...77,782,593
Ensembl chr16:77,671,023...77,782,697
|
|
G |
Arid3a |
AT-rich interaction domain 3A |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of ARID3A mRNA |
CTD |
PMID:23410634 |
|
NCBI chr 7:9,755,291...9,781,260
Ensembl chr 7:9,755,294...9,780,599
|
|
G |
Arl6ip1 |
ARL6 interacting reticulophagy regulator 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ARL6IP1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:172,430,475...172,439,990
Ensembl chr 1:172,430,489...172,439,994
|
|
G |
Arl6ip5 |
ARF like GTPase 6 interacting protein 5 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ARL6IP5 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:129,810,650...129,838,628
Ensembl chr 4:129,810,645...129,838,608
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
multiple interactions |
ISO |
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of ARNT mRNA; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of ARNT mRNA] |
CTD |
PMID:35690295 |
|
NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580
|
|
G |
Arpc1a |
actin related protein 2/3 complex, subunit 1A |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ARPC1A mRNA |
CTD |
PMID:15336504 |
|
NCBI chr12:9,502,496...9,525,304
Ensembl chr12:9,502,501...9,525,330
|
|
G |
Asf1a |
anti-silencing function 1A histone chaperone |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ASF1A mRNA |
CTD |
PMID:23410634 |
|
NCBI chr20:32,893,962...32,908,808
Ensembl chr20:32,893,573...32,908,808
|
|
G |
Asf1b |
anti-silencing function 1B histone chaperone |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ASF1B mRNA |
CTD |
PMID:15336504 |
|
NCBI chr19:24,181,024...24,195,604
Ensembl chr19:24,181,028...24,195,549
|
|
G |
Asph |
aspartate-beta-hydroxylase |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ASPH mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 5:22,601,581...22,814,107
Ensembl chr 5:22,603,486...22,813,876
|
|
G |
Aspscr1 |
ASPSCR1 tether for SLC2A4, UBX domain containing |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ASPSCR1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:105,952,215...105,990,059
Ensembl chr10:105,952,227...105,989,904
|
|
G |
Ass1 |
argininosuccinate synthase 1 |
decreases expression |
ISO EXP |
tert-Butylhydroperoxide results in decreased expression of ASS1 mRNA; tert-Butylhydroperoxide results in decreased expression of ASS1 protein |
CTD |
PMID:15336504 PMID:24394546 |
|
NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903
|
|
G |
Asxl1 |
ASXL transcriptional regulator 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ASXL1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:141,814,012...141,881,526
Ensembl chr 3:141,813,433...141,881,538
|
|
G |
Atad2 |
ATPase family, AAA domain containing 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ATAD2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:89,634,123...89,676,738
Ensembl chr 7:89,634,123...89,676,738
|
|
G |
Atf3 |
activating transcription factor 3 |
multiple interactions decreases expression increases expression |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of ATF3 mRNA; [rosiglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of ATF3 mRNA; [troglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of ATF3 mRNA; rosiglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ATF3 mRNA]; troglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ATF3 mRNA] tert-Butylhydroperoxide results in decreased expression of ATF3 mRNA |
CTD |
PMID:12414654 PMID:20196124 PMID:20847119 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atg4b |
autophagy related 4B, cysteine peptidase |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ATG4B mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 9:94,282,417...94,314,109
Ensembl chr 9:94,282,509...94,314,103
|
|
G |
Atg5 |
autophagy related 5 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ATG5 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Atp13a3 |
ATPase 13A3 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ATP13A3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr11:70,364,998...70,442,005
Ensembl chr11:70,365,322...70,441,235
|
|
G |
Atp2a2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ATP2A2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101
|
|
G |
Atp2b1 |
ATPase plasma membrane Ca2+ transporting 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ATP2B1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:33,735,595...33,845,226
Ensembl chr 7:33,735,871...33,843,295
|
|
G |
Atp6v1a |
ATPase H+ transporting V1 subunit A |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ATP6V1A mRNA |
CTD |
PMID:15336504 |
|
NCBI chr11:56,561,444...56,614,694
Ensembl chr11:56,560,974...56,614,694
|
|
G |
Atp6v1c1 |
ATPase H+ transporting V1 subunit C1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ATP6V1C1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:69,834,464...69,872,278
Ensembl chr 7:69,834,463...69,872,278
|
|
G |
Atr |
ATR serine/threonine kinase |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ATR mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 8:96,426,704...96,524,152
Ensembl chr 8:96,426,724...96,524,136
|
|
G |
Atxn1 |
ataxin 1 |
affects localization decreases expression multiple interactions |
ISO |
tert-Butylhydroperoxide affects the localization of ATXN1 protein mutant form tert-Butylhydroperoxide results in decreased expression of ATXN1 mRNA Acetylcysteine inhibits the reaction [tert-Butylhydroperoxide affects the localization of ATXN1 protein mutant form]; Buthionine Sulfoximine promotes the reaction [tert-Butylhydroperoxide affects the localization of ATXN1 protein mutant form] |
CTD |
PMID:12893416 PMID:15336504 |
|
NCBI chr17:18,737,491...19,142,360
Ensembl chr17:18,737,533...19,142,360
|
|
G |
Atxn3 |
ataxin 3 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ATXN3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 6:121,072,228...121,107,902
Ensembl chr 6:121,074,448...121,107,902
|
|
G |
Aurka |
aurora kinase A |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of AURKA mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 3:161,128,309...161,144,524
Ensembl chr 3:161,128,313...161,144,390
|
|
G |
Aurkb |
aurora kinase B |
decreases expression increases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of AURKB mRNA tert-Butylhydroperoxide results in increased expression of AURKB mRNA |
CTD |
PMID:12414654 PMID:29432895 |
|
NCBI chr10:53,744,290...53,750,831
Ensembl chr10:53,745,142...53,750,837
|
|
G |
Auts2 |
activator of transcription and developmental regulator AUTS2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of AUTS2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr12:24,104,187...25,194,123
Ensembl chr12:24,104,192...25,194,416
|
|
G |
Azin1 |
antizyme inhibitor 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of AZIN1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:69,654,773...69,681,578
Ensembl chr 7:69,654,663...69,681,578
|
|
G |
Babam1 |
BRISC and BRCA1 A complex member 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BABAM1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr16:18,068,830...18,074,938
Ensembl chr16:18,068,884...18,074,923
|
|
G |
Babam2 |
BRISC and BRCA1 A complex member 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of BABAM2 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 6:24,369,021...24,788,416
Ensembl chr 6:24,369,022...24,833,951
|
|
G |
Bace2 |
beta-secretase 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BACE2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr11:36,707,447...36,789,550
Ensembl chr11:36,707,458...36,789,546
|
|
G |
Bad |
BCL2-associated agonist of cell death |
decreases expression increases expression multiple interactions |
ISO EXP |
tert-Butylhydroperoxide results in decreased expression of BAD mRNA tert-Butylhydroperoxide results in increased expression of BAD protein Curcumin inhibits the reaction [tert-Butylhydroperoxide results in increased expression of BAD protein] |
CTD |
PMID:12419474 PMID:15569404 PMID:17419000 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BAK1 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bambi |
BMP and activin membrane-bound inhibitor |
decreases expression affects expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BAMBI mRNA tert-Butylhydroperoxide affects the expression of BAMBI mRNA |
CTD |
PMID:15336504 PMID:23410634 |
|
NCBI chr17:54,121,251...54,125,816
Ensembl chr17:54,121,255...54,126,060
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions affects localization increases expression decreases expression |
ISO EXP |
1-(3,4-dihydroxyphenyl)-3-(2-methoxyphenyl)prop-2-en-1-one inhibits the reaction [tert-Butylhydroperoxide results in increased expression of BAX protein]; [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of BAX mRNA; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of BAX mRNA]; hyperoside inhibits the reaction [tert-Butylhydroperoxide affects the localization of BAX protein]; LY96 protein affects the reaction [tert-Butylhydroperoxide results in increased expression of BAX protein]; LY96 protein promotes the reaction [tert-Butylhydroperoxide results in increased expression of BAX protein]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of BAX mRNA]; Peptides inhibits the reaction [tert-Butylhydroperoxide results in increased expression of BAX protein] acadesine inhibits the reaction [tert-Butylhydroperoxide results in increased expression of BAX protein]; Curcumin inhibits the reaction [tert-Butylhydroperoxide results in increased expression of BAX protein]; Fenofibrate inhibits the reaction [tert-Butylhydroperoxide results in increased expression of BAX protein] tert-Butylhydroperoxide results in decreased expression of BAX mRNA |
CTD |
PMID:12419474 PMID:15569404 PMID:17419000 PMID:18552516 PMID:20510348 PMID:23994092 PMID:25522270 PMID:26989860 PMID:28063877 PMID:29111459 PMID:35690295 More...
|
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Baz1b |
bromodomain adjacent to zinc finger domain, 1B |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BAZ1B mRNA |
CTD |
PMID:15336504 |
|
NCBI chr12:21,431,985...21,489,956
Ensembl chr12:21,431,985...21,490,426
|
|
G |
Bbln |
bublin coiled coil protein |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BBLN mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:15,674,577...15,677,322
Ensembl chr 3:15,674,580...15,677,374
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression affects localization |
EXP ISO |
acadesine inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of BCL2 protein]; Curcumin inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of BCL2 protein]; Fenofibrate inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of BCL2 protein]; Plant Extracts inhibits the reaction [tert-Butylhydroperoxide affects the localization of BCL2 protein]; Plant Extracts inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of BCL2 protein]; Silymarin inhibits the reaction [tert-Butylhydroperoxide affects the localization of BCL2 protein]; Silymarin inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of BCL2 protein] 1-(3,4-dihydroxyphenyl)-3-(2-methoxyphenyl)prop-2-en-1-one inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of BCL2 protein]; 3,4-dihydroxyphenyllactic acid inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of BCL2 protein]; [Deferoxamine co-treated with tert-Butylhydroperoxide] results in decreased expression of BCL2 mRNA; Genistein inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of BCL2 protein]; LY96 protein affects the reaction [tert-Butylhydroperoxide results in decreased expression of BCL2 protein]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in decreased expression of BCL2 mRNA]; Peptides inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of BCL2 protein]; Plant Extracts inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of BCL2 protein]; Quercetin inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of BCL2 protein] tert-Butylhydroperoxide results in decreased expression of BCL2 mRNA; tert-Butylhydroperoxide results in decreased expression of BCL2 protein |
CTD |
PMID:12782109 PMID:15288519 PMID:15569404 PMID:17419000 PMID:19772912 PMID:20510348 PMID:22659508 PMID:23994092 PMID:25522270 PMID:26989860 PMID:27050144 PMID:29111459 PMID:29128606 PMID:35690295 More...
|
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions decreases expression |
EXP ISO |
Curcumin inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of BCL2L1 protein] tert-Butylhydroperoxide results in decreased expression of BCL2L1 mRNA; tert-Butylhydroperoxide results in decreased expression of BCL2L1 protein Plant Extracts inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of BCL2L1 protein]; puag-haad inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of BCL2L1 protein]; Quercetin inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of BCL2L1 protein] |
CTD |
PMID:12419474 PMID:15569404 PMID:26102008 PMID:27050144 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Bcl2l13 |
Bcl2-like 13 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BCL2L13 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:154,056,116...154,112,890
Ensembl chr 4:154,056,127...154,108,985
|
|
G |
Bdh1 |
3-hydroxybutyrate dehydrogenase 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BDH1 mRNA |
CTD |
PMID:29432895 |
|
NCBI chr11:69,302,534...69,343,173
Ensembl chr11:69,302,534...69,337,671
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of BDNF mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Bex2 |
brain expressed X-linked 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of BEX1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr X:99,019,847...99,021,375
Ensembl chr X:99,019,000...99,021,503
|
|
G |
Bex4 |
brain expressed, X-linked 4 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of BEX4 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr X:99,131,985...99,133,417
Ensembl chr X:99,131,942...99,133,531
|
|
G |
Bhmt |
betaine-homocysteine S-methyltransferase |
increases methylation decreases expression |
ISO |
tert-Butylhydroperoxide results in increased methylation of BHMT gene tert-Butylhydroperoxide results in decreased expression of BHMT mRNA |
CTD |
PMID:27509014 |
|
NCBI chr 2:24,859,871...24,879,449
Ensembl chr 2:24,859,873...24,879,742
|
|
G |
Bicd1 |
BICD cargo adaptor 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BICD1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:182,479,071...182,631,504
Ensembl chr 4:182,479,071...182,627,434
|
|
G |
Bik |
BCL2-interacting killer |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of BIK mRNA |
CTD |
PMID:23410634 |
|
NCBI chr 7:114,672,277...114,691,296
Ensembl chr 7:114,672,277...114,691,296
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of BIRC5 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Bles03 |
basophilic leukemia expressed protein BLES03 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of C11ORF68 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:202,734,555...202,736,809
Ensembl chr 1:202,734,555...202,736,804
|
|
G |
Blnk |
B-cell linker |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of BLNK mRNA |
CTD |
PMID:14729362 |
|
NCBI chr 1:239,753,640...239,821,113
Ensembl chr 1:239,753,648...239,821,113
|
|
G |
Bmal2 |
basic helix-loop-helix ARNT like 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BMAL2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:179,699,432...179,747,710
Ensembl chr 4:179,699,502...179,746,949
|
|
G |
Bmerb1 |
bMERB domain containing 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BMERB1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:1,779,834...1,946,586
Ensembl chr10:1,779,835...1,946,575
|
|
G |
Bmp1 |
bone morphogenetic protein 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BMP1 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr15:45,551,603...45,595,862
Ensembl chr15:45,551,603...45,595,776
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BMP4 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
decreases expression increases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BNIP3 mRNA tert-Butylhydroperoxide results in increased expression of BNIP3 mRNA |
CTD |
PMID:12419474 PMID:15003993 |
|
NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
Bora |
bora, aurora kinase A activator |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BORA mRNA |
CTD |
PMID:15336504 |
|
NCBI chr15:75,797,624...75,835,599
Ensembl chr15:75,797,891...75,821,322
|
|
G |
Braf |
B-Raf proto-oncogene, serine/threonine kinase |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BRAF mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463
|
|
G |
Brd3 |
bromodomain containing 3 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BRD3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:10,773,163...10,829,675
Ensembl chr 3:10,775,272...10,829,577
|
|
G |
Brd3os |
BRD3 opposite strand |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BRD3OS mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:10,770,229...10,771,860
|
|
G |
Bscl2 |
BSCL2 lipid droplet biogenesis associated, seipin |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of BSCL2 mRNA |
CTD |
PMID:22003191 |
|
NCBI chr 1:205,731,828...205,743,430
Ensembl chr 1:205,733,872...205,743,421
|
|
G |
Bst1 |
bone marrow stromal cell antigen 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BST1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr14:67,253,706...67,270,203
Ensembl chr14:67,252,998...67,270,180
|
|
G |
Bst2 |
bone marrow stromal cell antigen 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BST2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr16:18,216,605...18,220,979
Ensembl chr16:18,217,407...18,220,979
|
|
G |
Btbd2 |
BTB domain containing 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BTBD2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:9,058,609...9,075,341
Ensembl chr 7:9,060,788...9,075,344
|
|
G |
Btd |
biotinidase |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BTD mRNA |
CTD |
PMID:15336504 |
|
NCBI chr16:6,863,068...6,894,345
Ensembl chr16:6,862,407...6,940,945
|
|
G |
Btf3 |
basic transcription factor 3 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of BTF3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 2:29,659,764...29,666,898
Ensembl chr 2:29,659,231...29,666,879 Ensembl chr13:29,659,231...29,666,879
|
|
G |
Btg1 |
BTG anti-proliferation factor 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BTG1 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 7:31,341,391...31,343,649
Ensembl chr 7:31,341,027...31,343,649
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of BTG2 mRNA |
CTD |
PMID:12414654 PMID:21382384 |
|
NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628
|
|
G |
Bub1 |
BUB1 mitotic checkpoint serine/threonine kinase |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of BUB1 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr 3:115,020,254...115,051,650
Ensembl chr 3:115,020,254...115,051,650
|
|
G |
Bud23 |
BUD23, rRNA methyltransferase and ribosome maturation factor |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BUD23 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr12:21,629,551...21,640,758
Ensembl chr12:21,629,536...21,640,751
|
|
G |
Bzw1 |
basic leucine zipper and W2 domains 1 |
multiple interactions increases expression |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of BZW1 mRNA; [rosiglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of BZW1 mRNA; pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of BZW1 mRNA]; rosiglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of BZW1 mRNA]; troglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of BZW1 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr 9:59,930,672...59,944,468
Ensembl chr 9:59,930,744...59,944,430
|
|
G |
C10h17orf100 |
similar to human chromosome 17 open reading frame 100 |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of C17ORF100 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr10:56,840,451...56,843,674
Ensembl chr10:56,832,412...56,843,871
|
|
G |
C13h1orf115 |
similar to human chromosome 1 open reading frame 115 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of C1ORF115 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr13:96,422,308...96,432,044
Ensembl chr13:96,422,302...96,432,068
|
|
G |
C17h6orf62 |
similar to human chromosome 6 open reading frame 62 |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of C6ORF62 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr17:40,256,211...40,267,851
Ensembl chr17:40,256,211...40,276,020
|
|
G |
C1r |
complement C1r |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of C1R mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:157,412,718...157,423,483
Ensembl chr 4:157,412,692...157,423,484
|
|
G |
C2cd2 |
C2 calcium-dependent domain containing 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of C2CD2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr11:37,225,321...37,289,741
Ensembl chr11:37,227,415...37,289,739
|
|
G |
C5 |
complement C5 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of C5 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:18,270,696...18,361,994
Ensembl chr 3:18,270,696...18,361,994
|
|
G |
C7h8orf76 |
similar to human chromosome 8 open reading frame 76 |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of C8ORF76 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr 7:89,558,890...89,569,810
Ensembl chr 7:89,558,909...89,569,810
|
|
G |
Cadm1 |
cell adhesion molecule 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CADM1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 8:47,847,836...48,178,703
Ensembl chr 8:47,847,325...48,182,833
|
|
G |
Cadm4 |
cell adhesion molecule 4 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CADM4 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:80,075,163...80,097,423
Ensembl chr 1:80,075,202...80,097,423
|
|
G |
Calhm2 |
calcium homeostasis modulator family member 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CALHM2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:246,022,324...246,028,050
Ensembl chr 1:246,022,324...246,028,218
|
|
G |
Calm1 |
calmodulin 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CALM1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 6:119,487,691...119,495,759
Ensembl chr 6:119,487,621...119,498,227
|
|
G |
Calm3 |
calmodulin 3 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CALM3 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 1:77,590,668...77,597,776
Ensembl chr 1:77,589,230...77,592,207
|
|
G |
Calml4 |
calmodulin-like 4 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CALML4 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 8:63,323,426...63,335,234
Ensembl chr 8:63,323,351...63,335,234
|
|
G |
Calr |
calreticulin |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CALR mRNA |
CTD |
PMID:15336504 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Calu |
calumenin |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CALU mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:57,949,086...57,976,589
Ensembl chr 4:57,948,997...57,976,593
|
|
G |
Camk2n1 |
calcium/calmodulin-dependent protein kinase II inhibitor 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CAMK2N1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 5:150,674,819...150,676,600
Ensembl chr 5:150,673,507...150,676,600
|
|
G |
Camlg |
calcium modulating ligand |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CAML mRNA |
CTD |
PMID:14729362 |
|
NCBI chr17:8,992,697...9,003,576
Ensembl chr17:8,992,696...9,003,552
|
|
G |
Camp |
cathelicidin antimicrobial peptide |
decreases expression |
EXP |
tert-Butylhydroperoxide results in decreased expression of CAMP mRNA |
CTD |
PMID:22659508 |
|
NCBI chr 8:109,841,729...109,843,543
Ensembl chr 8:109,841,729...109,843,543
|
|
G |
Cand1 |
cullin-associated and neddylation-dissociated 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CAND1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:54,681,114...54,719,002
Ensembl chr 7:54,680,900...54,718,993
|
|
G |
Capn1 |
calpain 1 |
increases response to substance increases expression |
ISO |
CAPN1 protein results in increased susceptibility to tert-Butylhydroperoxide tert-Butylhydroperoxide results in increased expression of CAPN1 mRNA |
CTD |
PMID:12842444 PMID:15003993 |
|
NCBI chr 1:203,275,912...203,300,848
Ensembl chr 1:203,277,344...203,300,177
|
|
G |
Capn2 |
calpain 2 |
decreases expression affects expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CAPN2 mRNA tert-Butylhydroperoxide affects the expression of CAPN2 mRNA |
CTD |
PMID:12419474 PMID:23410634 |
|
NCBI chr13:94,150,244...94,200,969
Ensembl chr13:94,150,240...94,200,969
|
|
G |
Capn5 |
calpain 5 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CAPN5 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 1:152,416,252...152,472,923
Ensembl chr 1:152,416,252...152,472,923
|
|
G |
Capn7 |
calpain 7 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CAPN7 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr16:6,545,630...6,581,908
Ensembl chr16:6,545,731...6,581,905
|
|
G |
Capns1 |
calpain, small subunit 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CAPNS1 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 1:85,444,613...85,454,861
Ensembl chr 1:85,444,608...85,454,795
|
|
G |
Caprin2 |
caprin family member 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CAPRIN2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:181,806,105...181,860,754
Ensembl chr 4:181,806,575...181,860,830
|
|
G |
Car8 |
carbonic anhydrase 8 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CA8 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 5:21,302,940...21,402,395
Ensembl chr 5:21,305,383...21,402,374
|
|
G |
Cars2 |
cysteinyl-tRNA synthetase 2, mitochondrial |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CARS2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr16:77,945,468...77,987,163
Ensembl chr16:77,950,008...77,987,772
|
|
G |
Cask |
calcium/calmodulin dependent serine protein kinase |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CASK mRNA |
CTD |
PMID:12419474 |
|
NCBI chr X:8,899,500...9,243,014
Ensembl chr X:8,899,833...9,238,694
|
|
G |
Casp3 |
caspase 3 |
multiple interactions decreases activity increases cleavage decreases expression increases activity increases expression |
ISO EXP |
1-(3,4-dihydroxyphenyl)-3-(2-methoxyphenyl)prop-2-en-1-one inhibits the reaction [tert-Butylhydroperoxide results in increased expression of CASP3 protein modified form]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [rutecarpine inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein]]; [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CASP3 mRNA; acetyl-aspartyl-glutamyl-valyl-aspartal inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein]; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CASP3 mRNA]; Drugs, Chinese Herbal inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of CASP3 protein]; GPX4 protein inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein]; KN 93 inhibits the reaction [rutecarpine inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein]]; LY96 protein promotes the reaction [tert-Butylhydroperoxide results in increased expression of CASP3 protein modified form]; MCL1 protein inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CASP3 mRNA]; N-(3-methoxyphenyl)-4-chlorocinnamanilide inhibits the reaction [rutecarpine inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein]]; nectandrin-B inhibits the reaction [tert-Butylhydroperoxide results in increased cleavage of CASP3 protein]; PAFAH2 protein inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein]; puag-haad inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of CASP3 protein]; rutecarpine inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein]; zinc protoporphyrin inhibits the reaction [rutecarpine inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein]] tert-butylhydroperoxide decreases activity of Casp3 protein in hepatocyte cytosol acadesine inhibits the reaction [tert-Butylhydroperoxide results in increased cleavage of CASP3 protein]; Curcumin inhibits the reaction [tert-Butylhydroperoxide results in increased cleavage of CASP3 protein]; Fenofibrate inhibits the reaction [tert-Butylhydroperoxide results in increased cleavage of CASP3 protein]; Plant Extracts inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein]; Silymarin inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein] 6,7-dihydroxyflavone inhibits the reaction [tert-Butylhydroperoxide results in increased cleavage of CASP3 protein]; caffeoylquinic acid analog inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein]; Catechin inhibits the reaction [tert-Butylhydroperoxide results in increased cleavage of CASP3 protein]; Drugs, Chinese Herbal inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein]; tert-Butylhydroperoxide results in increased expression of and results in increased cleavage of CASP3 protein tert-Butylhydroperoxide results in increased expression of CASP3 protein; tert-Butylhydroperoxide results in increased expression of CASP3 protein modified form |
CTD RGD |
PMID:12406338 PMID:15496407 PMID:15569404 PMID:15611089 PMID:15877105 PMID:16753784 PMID:17419000 PMID:19647727 PMID:19772912 PMID:20510348 PMID:20847119 PMID:26102008 PMID:26989860 PMID:27511913 PMID:28025122 PMID:28063877 PMID:28733231 PMID:35690295 PMID:38053484 PMID:18316105 More...
|
RGD:2311460 |
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp6 |
caspase 6 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CASP6 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502
|
|
G |
Casp7 |
caspase 7 |
multiple interactions decreases activity increases cleavage |
ISO EXP |
Plant Extracts inhibits the reaction [tert-Butylhydroperoxide results in increased cleavage of CASP7 protein]; Quercetin inhibits the reaction [tert-Butylhydroperoxide results in increased cleavage of CASP7 protein] tert-butylhydroperoxide decreases activity of Casp7 protein in hepatocyte cytosol |
CTD RGD |
PMID:27050144 PMID:18316105 |
RGD:2311460 |
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CASP8 mRNA; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CASP8 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CASP8 mRNA] |
CTD |
PMID:35690295 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases cleavage decreases activity multiple interactions increases expression |
EXP ISO |
tert-Butylhydroperoxide results in increased cleavage of CASP9 protein Tert-butylhydroperoxide decreases activity of Casp9 protein in hepatocyte cytosol Plant Extracts inhibits the reaction [tert-Butylhydroperoxide results in increased cleavage of CASP9 protein]; Quercetin inhibits the reaction [tert-Butylhydroperoxide results in increased cleavage of CASP9 protein] tert-Butylhydroperoxide results in increased expression of CASP9 protein Plant Extracts inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP9 protein]; Silymarin inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP9 protein] |
CTD RGD |
PMID:15877105 PMID:17003459 PMID:19772912 PMID:20510348 PMID:27050144 PMID:18316105 More...
|
RGD:2311460 |
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cast |
calpastatin |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CAST mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 2:3,973,112...4,082,658
Ensembl chr 2:3,973,112...4,082,659
|
|
G |
Cat |
catalase |
affects response to substance increases activity decreases activity multiple interactions increases expression decreases expression decreases response to substance |
ISO EXP |
CAT protein affects the susceptibility to tert-Butylhydroperoxide tert-Butylhydroperoxide results in increased activity of CAT protein tert-Butylhydroperoxide results in decreased activity of CAT protein CAT protein results in increased susceptibility to [tert-Butylhydroperoxide co-treated with Desoxycorticosterone co-treated with tempol] tert-Butylhydroperoxide results in increased expression of CAT mRNA CAT protein inhibits the reaction [tert-Butylhydroperoxide results in increased expression of FOS mRNA]; CAT protein inhibits the reaction [tert-Butylhydroperoxide results in increased expression of JUN mRNA]; Catechin inhibits the reaction [tert-Butylhydroperoxide results in decreased activity of CAT protein] tert-Butylhydroperoxide results in decreased expression of CAT mRNA; tert-Butylhydroperoxide results in decreased expression of CAT protein [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CAT mRNA; Oleanolic Acid inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of CAT protein]; Quercetin inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CAT protein] CAT protein results in decreased susceptibility to tert-Butylhydroperoxide |
CTD |
PMID:10754530 PMID:11178967 PMID:12423650 PMID:12628296 PMID:12646410 PMID:14729362 PMID:15003993 PMID:15105052 PMID:15207383 PMID:15336504 PMID:15849717 PMID:16126241 PMID:16753784 PMID:16928893 PMID:17003459 PMID:20100471 PMID:34303734 PMID:35690295 More...
|
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cav1 |
caveolin 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CAV1 mRNA |
CTD |
PMID:15963989 |
|
NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705
|
|
G |
Cav2 |
caveolin 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CAV2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:45,616,766...45,624,144
Ensembl chr 4:45,616,712...45,624,244
|
|
G |
Cavin2 |
caveolae associated protein 2 |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of CAVIN2 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr 9:50,302,079...50,314,096
Ensembl chr 9:50,301,206...50,314,147
|
|
G |
Cbfb |
core-binding factor subunit beta |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CBFB mRNA |
CTD |
PMID:15336504 |
|
NCBI chr19:33,049,162...33,092,752
Ensembl chr19:33,049,172...33,092,751
|
|
G |
Cbr3 |
carbonyl reductase 3 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CBR3 mRNA |
CTD |
PMID:21382384 |
|
NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875
|
|
G |
Cbs |
cystathionine beta synthase |
decreases expression increases methylation |
ISO |
tert-Butylhydroperoxide results in decreased expression of CBS mRNA tert-Butylhydroperoxide results in increased methylation of CBS gene |
CTD |
PMID:15336504 PMID:27509014 |
|
NCBI chr20:9,708,089...9,732,623
Ensembl chr20:9,708,090...9,732,764
|
|
G |
Ccdc25 |
coiled-coil domain containing 25 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CCDC25 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr15:40,055,368...40,087,758
Ensembl chr15:40,055,368...40,087,758
|
|
G |
Ccdc86 |
coiled-coil domain containing 86 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CCDC86 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:207,590,167...207,596,547
Ensembl chr 1:207,590,168...207,596,544
|
|
G |
Ccdc93 |
coiled-coil domain containing 93 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CCDC93 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr13:32,607,618...32,675,993
Ensembl chr13:32,607,587...32,676,023
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions decreases expression |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of CCL2 mRNA; [rosiglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of CCL2 mRNA; [troglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of CCL2 mRNA; tert-Butylhydroperoxide promotes the reaction [PPARG protein binds to CCL2 promoter]; troglitazone inhibits the reaction [tert-Butylhydroperoxide promotes the reaction [PPARG protein binds to CCL2 promoter]]; troglitazone inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of CCL2 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CCL5 mRNA |
CTD |
PMID:14729362 PMID:15003993 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccn1 |
cellular communication network factor 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CCN1 mRNA |
CTD |
PMID:12414654 PMID:15336504 |
|
NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions affects expression decreases expression |
ISO |
[Pioglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of CCN2 mRNA; [Rosiglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of CCN2 mRNA; [Troglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of CCN2 mRNA; Pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of CCN2 mRNA]; Troglitazone inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of CCN2 mRNA] tert-Butylhydroperoxide affects the expression of CCN2 mRNA |
CTD |
PMID:20847119 PMID:23410634 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccn3 |
cellular communication network factor 3 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CCN3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:86,094,000...86,101,022
Ensembl chr 7:86,094,000...86,101,019
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression affects expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CCNA2 mRNA tert-Butylhydroperoxide affects the expression of CCNA2 mRNA |
CTD |
PMID:12414654 PMID:12419474 PMID:15336504 PMID:23410634 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb2 |
cyclin B2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CCNB2 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874
|
|
G |
Ccne1 |
cyclin E1 |
multiple interactions |
ISO |
ginsenoside Rg1 affects the reaction [tert-Butylhydroperoxide affects the expression of CCNE1 protein] |
CTD |
PMID:15606011 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Ccne2 |
cyclin E2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CCNE2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 5:24,285,078...24,298,258
Ensembl chr 5:24,284,922...24,297,632
|
|
G |
Ccnf |
cyclin F |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CCNF mRNA |
CTD |
PMID:15003993 |
|
NCBI chr10:13,253,073...13,279,140
Ensembl chr10:13,253,380...13,279,101
|
|
G |
Ccng2 |
cyclin G2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CCNG2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr14:14,804,321...14,812,819
Ensembl chr14:14,804,322...14,812,830
|
|
G |
Ccnj |
cyclin J |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CCNJ mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:239,659,588...239,677,367
|
|
G |
Ccnk |
cyclin K |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CCNK mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 6:127,090,115...127,113,195
Ensembl chr 6:127,090,569...127,113,191
|
|
G |
Ccs |
copper chaperone for superoxide dismutase |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CCS mRNA |
CTD |
PMID:14729362 PMID:15336504 |
|
NCBI chr 1:202,113,792...202,134,931
Ensembl chr 1:202,113,804...202,134,915
|
|
G |
Cd24 |
CD24 molecule |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CD24 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr20:47,074,353...47,079,662
Ensembl chr20:47,073,512...47,079,662
|
|
G |
Cd320 |
CD320 molecule |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CD320 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:14,626,171...14,631,976
Ensembl chr 7:14,609,146...14,631,976
|
|
G |
Cd46 |
CD46 molecule |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CD46 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr13:106,575,586...106,606,325
Ensembl chr13:106,574,858...106,660,445
|
|
G |
Cd47 |
Cd47 molecule |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CD47 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr11:50,906,052...50,970,000
Ensembl chr11:50,906,177...50,969,425
|
|
G |
Cd55 |
CD55 molecule (Cromer blood group) |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CD55 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr13:41,857,242...41,885,966
Ensembl chr13:41,857,395...41,885,831
|
|
G |
Cd68 |
Cd68 molecule |
increases expression decreases response to substance |
ISO |
tert-Butylhydroperoxide results in increased expression of CD68 mRNA CD68 protein results in decreased susceptibility to tert-Butylhydroperoxide |
CTD |
PMID:14729362 PMID:15003993 PMID:15336504 |
|
NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697
|
|
G |
Cd82 |
Cd82 molecule |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CD82 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:79,387,361...79,431,847
Ensembl chr 3:79,385,887...79,431,809
|
|
G |
Cd9 |
CD9 molecule |
decreases expression affects expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CD9 mRNA tert-Butylhydroperoxide affects the expression of CD9 mRNA |
CTD |
PMID:15336504 PMID:23410634 |
|
NCBI chr 4:158,256,328...158,289,136
Ensembl chr 4:158,256,328...158,289,222
|
|
G |
Cd99 |
CD99 molecule (Xg blood group) |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CD99 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr20:54,418,239...54,422,882
|
|
G |
Cdc16 |
cell division cycle 16 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CDC16 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr16:75,773,026...75,796,586
Ensembl chr16:75,773,028...75,796,550
|
|
G |
Cdc25b |
cell division cycle 25B |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CDC25B mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:118,407,127...118,417,272
Ensembl chr 3:118,407,128...118,417,272
|
|
G |
Cdc25c |
cell division cycle 25C |
decreases expression increases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CDC25C mRNA tert-Butylhydroperoxide results in increased expression of CDC25C mRNA |
CTD |
PMID:12419474 PMID:14729362 PMID:15003993 |
|
NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
|
|
G |
Cdc27 |
cell division cycle 27 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CDC27 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:89,400,720...89,449,816
Ensembl chr10:89,400,940...89,449,736
|
|
G |
Cdc37l1 |
cell division cycle 37-like 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CDC37L1 mRNA |
CTD |
PMID:15963989 |
|
NCBI chr 1:226,705,019...226,733,994
Ensembl chr 1:226,705,003...226,761,175
|
|
G |
Cdc42 |
cell division cycle 42 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CDC42 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111
|
|
G |
Cdc42ep2 |
CDC42 effector protein 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CDC42EP2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:203,202,000...203,210,891
Ensembl chr 1:203,201,873...203,210,897
|
|
G |
Cdc42ep3 |
CDC42 effector protein 3 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CDC42EP3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 6:15,710,894...15,731,366
Ensembl chr 6:15,708,730...15,732,721
|
|
G |
Cdc42ep4 |
CDC42 effector protein 4 |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of CDC42EP4 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr10:98,772,613...98,797,924
Ensembl chr10:98,772,495...98,797,695
|
|
G |
Cdc42se1 |
CDC42 small effector 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CDC42SE1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 2:182,805,691...182,813,520
Ensembl chr 2:182,804,925...182,814,028
|
|
G |
Cdc5l |
cell division cycle 5-like |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CDC5L mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 9:15,564,949...15,603,453
Ensembl chr 9:15,564,767...15,603,450
|
|
G |
Cdca3 |
cell division cycle associated 3 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CDCA3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:157,634,775...157,638,799
Ensembl chr 4:157,634,928...157,638,799
|
|
G |
Cdcp1 |
CUB domain containing protein 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CDCP1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 8:122,828,685...122,865,345
Ensembl chr 8:122,828,685...122,865,388
|
|
G |
Cdh11 |
cadherin 11 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CDH11 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr19:2,148,447...2,305,754
Ensembl chr19:2,148,458...2,304,272
|
|
G |
Cdh3 |
cadherin 3 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CDH3 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr19:34,393,596...34,444,084
Ensembl chr19:34,393,727...34,444,084
|
|
G |
Cdh5 |
cadherin 5 |
increases expression |
EXP |
tert-Butylhydroperoxide results in increased expression of CDH5 mRNA |
CTD |
PMID:22659508 |
|
NCBI chr19:815,415...854,478
Ensembl chr19:815,411...854,368
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CDK1 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk10 |
cyclin-dependent kinase 10 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CDK10 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr19:51,260,012...51,273,009
Ensembl chr19:51,261,356...51,269,078
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases activity decreases expression multiple interactions |
ISO |
tert-Butylhydroperoxide results in decreased activity of CDK2 protein tert-Butylhydroperoxide results in decreased expression of CDK2 mRNA ginsenoside Rg1 affects the reaction [tert-Butylhydroperoxide affects the expression of CDK2 protein] |
CTD |
PMID:12766906 PMID:15336504 PMID:15606011 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression multiple interactions |
ISO |
tert-Butylhydroperoxide results in increased expression of CDKN1A mRNA; tert-Butylhydroperoxide results in increased expression of CDKN1A protein [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CDKN1A mRNA; ginsenoside Rg1 affects the reaction [tert-Butylhydroperoxide affects the expression of CDKN1A protein]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CDKN1A mRNA]; Niacinamide inhibits the reaction [tert-Butylhydroperoxide results in increased expression of CDKN1A protein]; Plant Extracts inhibits the reaction [tert-Butylhydroperoxide results in increased expression of CDKN1A protein] |
CTD |
PMID:12414654 PMID:12766906 PMID:12782109 PMID:15336504 PMID:15606011 PMID:18619952 PMID:22563892 PMID:35690295 More...
|
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions |
ISO |
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CDKN1B mRNA |
CTD |
PMID:35690295 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
multiple interactions increases expression decreases expression |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of CDKN1C mRNA; [rosiglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of CDKN1C mRNA; [troglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of CDKN1C mRNA; rosiglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of CDKN1C mRNA]; tert-Butylhydroperoxide promotes the reaction [PPARG protein binds to CDKN1C promoter]; troglitazone inhibits the reaction [tert-Butylhydroperoxide promotes the reaction [PPARG protein binds to CDKN1C promoter]]; troglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of CDKN1C mRNA] tert-Butylhydroperoxide results in decreased expression of CDKN1C mRNA |
CTD |
PMID:12419474 PMID:20847119 |
|
NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048
|
|
G |
Cdkn2b |
cyclin-dependent kinase inhibitor 2B |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CDKN2B mRNA |
CTD |
PMID:12419474 PMID:14729362 |
|
NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050
|
|
G |
Cdkn2c |
cyclin-dependent kinase inhibitor 2C |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CDKN2C mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 5:124,411,123...124,416,278
Ensembl chr 5:124,411,124...124,416,278
|
|
G |
Cdkn3 |
cyclin-dependent kinase inhibitor 3 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CDKN3 mRNA |
CTD |
PMID:15003993 PMID:27509014 |
|
NCBI chr15:20,022,522...20,033,948
Ensembl chr15:20,022,664...20,033,945
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of CEBPA mRNA |
CTD |
PMID:23410634 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CEBPB mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Celf2 |
CUGBP, Elav-like family member 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CELF2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr17:70,904,462...71,729,072
Ensembl chr17:71,210,853...71,728,333
|
|
G |
Celsr2 |
cadherin, EGF LAG seven-pass G-type receptor 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CELSR2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 2:196,029,206...196,053,848
Ensembl chr 2:196,029,434...196,053,845
|
|
G |
Cenpa |
centromere protein A |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CENPA mRNA |
CTD |
PMID:12414654 |
|
NCBI chr 6:25,700,142...25,711,767
Ensembl chr 6:25,700,142...25,711,675
|
|
G |
Cenpm |
centromere protein M |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CENPM mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:113,748,026...113,759,296
Ensembl chr 7:113,747,516...113,764,258
|
|
G |
Cep170 |
centrosomal protein 170 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CEP170 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr13:88,669,672...88,754,011
Ensembl chr13:88,670,358...88,732,226
|
|
G |
Cep170b |
centrosomal protein 170B |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CEP170B mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 6:131,780,935...131,806,658
Ensembl chr 6:131,778,957...131,806,658
|
|
G |
Cep192 |
centrosomal protein 192 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CEP192 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr18:61,373,937...61,458,405
Ensembl chr18:61,332,158...61,458,379
|
|
G |
Cep43 |
centrosomal protein 43 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CEP43 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:52,533,418...52,564,025
Ensembl chr 1:52,533,428...52,563,923
|
|
G |
Cep57 |
centrosomal protein 57 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CEP57 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 8:10,669,588...10,689,257
Ensembl chr 8:10,669,590...10,689,249
|
|
G |
Cep89 |
centrosomal protein 89 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CEP89 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 1:88,058,211...88,100,114
Ensembl chr 1:88,058,227...88,100,112
|
|
G |
Cfb |
complement factor B |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CFB mRNA |
CTD |
PMID:15336504 |
|
NCBI chr20:3,970,643...3,976,510
Ensembl chr20:3,951,474...3,976,505
|
|
G |
Cfi |
complement factor I |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CFI mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 2:218,389,079...218,430,565
Ensembl chr 2:218,387,990...218,430,561
|
|
G |
Chaf1a |
chromatin assembly factor 1 subunit A |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CHAF1A mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 9:873,953...900,701
Ensembl chr 9:874,051...900,654
|
|
G |
Chdh |
choline dehydrogenase |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CHDH mRNA |
CTD |
PMID:27509014 |
|
NCBI chr16:5,194,269...5,225,541
Ensembl chr16:5,194,269...5,225,537
|
|
G |
Chek1 |
checkpoint kinase 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CHEK1 mRNA |
CTD |
PMID:12414654 |
|
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Chka |
choline kinase alpha |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of CHKA mRNA |
CTD |
PMID:23410634 |
|
NCBI chr 1:201,076,804...201,125,517
Ensembl chr 1:201,076,860...201,125,516
|
|
G |
Chmp2a |
charged multivesicular body protein 2A |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CHMP2A mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:73,660,045...73,662,894
Ensembl chr 1:73,660,046...73,662,452
|
|
G |
Chordc1 |
cysteine and histidine rich domain containing 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CHORDC1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 8:15,374,356...15,398,436
Ensembl chr 8:15,374,471...15,399,162
|
|
G |
Chrdl1 |
chordin-like 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CHRDL1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr X:106,889,125...106,992,937
Ensembl chr X:106,889,125...106,992,921
|
|
G |
Chst15 |
carbohydrate sulfotransferase 15 |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of CHST15 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr 1:187,028,860...187,107,908
Ensembl chr 1:187,028,970...187,107,707
|
|
G |
Chst2 |
carbohydrate sulfotransferase 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CHST2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 8:95,960,067...95,966,312
Ensembl chr 8:95,959,826...95,966,955
|
|
G |
Clasp1 |
cytoplasmic linker associated protein 1 |
decreases methylation decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased methylation of CLASP1 intron tert-Butylhydroperoxide results in decreased expression of CLASP1 mRNA |
CTD |
PMID:29432895 |
|
NCBI chr13:29,493,554...29,715,151
Ensembl chr13:29,493,596...29,715,146
|
|
G |
Clcn3 |
chloride voltage-gated channel 3 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CLCN3 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr16:29,127,152...29,200,133
Ensembl chr16:29,127,419...29,200,119
|
|
G |
Clic3 |
chloride intracellular channel 3 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CLIC3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:8,271,416...8,274,023
Ensembl chr 3:8,272,097...8,274,018
|
|
G |
Cln3 |
CLN3 lysosomal/endosomal transmembrane protein, battenin |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CLN3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:181,156,071...181,169,458
Ensembl chr 1:181,156,073...181,167,434
|
|
G |
Cln6 |
CLN6, transmembrane ER protein |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CLN6 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 8:63,303,356...63,318,360
Ensembl chr 8:63,303,029...63,318,360
|
|
G |
Clstn1 |
calsyntenin 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CLSTN1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 5:160,031,235...160,094,585
Ensembl chr 5:160,031,308...160,094,583
|
|
G |
Clu |
clusterin |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CLU mRNA |
CTD |
PMID:15963989 |
|
NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315
|
|
G |
Cmtm1 |
CKLF-like MARVEL transmembrane domain containing 1 |
decreases methylation |
ISO |
tert-Butylhydroperoxide results in decreased methylation of CMTM1 gene |
CTD |
PMID:29432895 |
|
NCBI chr19:651,641...661,184
Ensembl chr19:651,644...661,184
|
|
G |
Cndp2 |
carnosine dipeptidase 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CNDP2 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr18:78,039,924...78,057,030
Ensembl chr18:78,039,932...78,056,922
|
|
G |
Cnnm3 |
cyclin and CBS domain divalent metal cation transport mediator 3 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CNNM3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 9:38,755,374...38,770,740
Ensembl chr 9:38,755,390...38,770,740
|
|
G |
Cnot8 |
CCR4-NOT transcription complex, subunit 8 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CNOT8 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:42,281,614...42,294,740
Ensembl chr10:42,281,722...42,294,730
|
|
G |
Cog5 |
component of oligomeric golgi complex 5 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of COG5 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 6:48,242,470...48,545,185
Ensembl chr 6:48,242,482...48,529,009
|
|
G |
Cog8 |
component of oligomeric golgi complex 8 |
multiple interactions decreases expression |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of COG8 mRNA; [rosiglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of COG8 mRNA; troglitazone inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of COG8 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr19:34,951,625...34,962,377
Ensembl chr19:34,951,627...34,962,397
|
|
G |
Col13a1 |
collagen type XIII alpha 1 chain |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of COL13A1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr20:29,783,965...29,924,116
Ensembl chr20:29,783,965...29,924,032
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of COL1A2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of COL3A1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Col4a1 |
collagen type IV alpha 1 chain |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of COL4A1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr16:78,183,533...78,294,412
Ensembl chr16:78,183,533...78,294,412
|
|
G |
Col4a2 |
collagen type IV alpha 2 chain |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of COL4A2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr16:78,047,591...78,183,360
Ensembl chr16:78,047,602...78,183,839
|
|
G |
Col5a1 |
collagen type V alpha 1 chain |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of COL5A1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:11,208,429...11,356,715
Ensembl chr 3:11,208,512...11,354,588
|
|
G |
Col5a2 |
collagen type V alpha 2 chain |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of COL5A2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 9:47,448,741...47,598,134
Ensembl chr 9:47,448,736...47,598,154
|
|
G |
Col6a1 |
collagen type VI alpha 1 chain |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of COL6A1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr20:11,906,105...11,924,599
Ensembl chr20:11,905,957...11,924,597
|
|
G |
Col6a2 |
collagen type VI alpha 2 chain |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of COL6A2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr20:12,021,676...12,049,425
Ensembl chr20:12,021,767...12,057,564
|
|
G |
Col7a1 |
collagen type VII alpha 1 chain |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of COL7A1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 8:109,604,877...109,637,249
Ensembl chr 8:109,604,861...109,637,252
|
|
G |
Col8a2 |
collagen type VIII alpha 2 chain |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of COL8A2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 5:138,586,201...138,613,627
Ensembl chr 5:138,585,999...138,612,850
|
|
G |
Comt |
catechol-O-methyltransferase |
decreases expression |
ISO EXP |
tert-Butylhydroperoxide results in decreased expression of COMT mRNA tert-Butylhydroperoxide results in decreased expression of COMT protein |
CTD |
PMID:12419474 PMID:24394546 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Copa |
COPI coat complex subunit alpha |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of COPA mRNA |
CTD |
PMID:15336504 |
|
NCBI chr13:84,546,483...84,586,879
Ensembl chr13:84,545,943...84,586,874
|
|
G |
Copb1 |
COPI coat complex subunit beta 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of COPB1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:168,404,334...168,438,589
Ensembl chr 1:168,404,335...168,438,416
|
|
G |
Cope |
COPI coat complex subunit epsilon |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of COPE mRNA |
CTD |
PMID:15336504 |
|
NCBI chr16:19,114,871...19,125,076
Ensembl chr16:19,114,871...19,128,907
|
|
G |
Cops6 |
COP9 signalosome subunit 6 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of COPS6 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr12:17,038,979...17,041,818
Ensembl chr12:17,038,979...17,046,371
|
|
G |
Cops8 |
COP9 signalosome subunit 8 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of COPS8 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 9:91,207,427...91,217,258
Ensembl chr 9:91,207,395...91,217,258
|
|
G |
Cox7a1 |
cytochrome c oxidase subunit 7A1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of COX7A1 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 1:85,422,162...85,447,530
Ensembl chr 1:85,441,871...85,445,151
|
|
G |
Cp |
ceruloplasmin |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CP mRNA |
CTD |
PMID:14729362 |
|
NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075
|
|
G |
Cpe |
carboxypeptidase E |
decreases expression increases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CPE mRNA tert-Butylhydroperoxide results in increased expression of CPE mRNA |
CTD |
PMID:12419474 PMID:15336504 |
|
NCBI chr16:25,030,276...25,142,231
Ensembl chr16:25,030,276...25,142,233
|
|
G |
Cpm |
carboxypeptidase M |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CPM mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:53,225,647...53,286,220
Ensembl chr 7:53,225,696...53,286,220
|
|
G |
Cpne1 |
copine 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CPNE1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:144,587,531...144,629,911
Ensembl chr 3:144,588,995...144,598,636
|
|
G |
Cpq |
carboxypeptidase Q |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CPQ mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:64,264,025...64,830,867
Ensembl chr 7:64,264,081...64,724,546
|
|
G |
Crat |
carnitine O-acetyltransferase |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CRAT mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:13,675,684...13,689,282
Ensembl chr 3:13,675,684...13,689,255
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
decreases expression increases phosphorylation multiple interactions |
ISO |
tert-Butylhydroperoxide results in decreased expression of CREB1 mRNA tert-Butylhydroperoxide results in increased phosphorylation of CREB1 protein U 0126 inhibits the reaction [tert-Butylhydroperoxide results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:12419474 PMID:17003459 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crip1 |
cysteine rich protein 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CRIP1 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 6:132,226,746...132,234,620
Ensembl chr 6:132,226,746...132,234,620
|
|
G |
Crispld2 |
cysteine-rich secretory protein LCCL domain containing 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CRISPLD2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr19:48,053,153...48,111,485
Ensembl chr19:48,053,287...48,110,465
|
|
G |
Cryab |
crystallin, alpha B |
multiple interactions decreases expression increases expression |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of CRYAB mRNA; [rosiglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of CRYAB mRNA; [troglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of CRYAB mRNA; pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of CRYAB mRNA]; troglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of CRYAB mRNA] tert-Butylhydroperoxide results in decreased expression of CRYAB mRNA |
CTD |
PMID:15336504 PMID:20847119 |
|
NCBI chr 8:51,093,441...51,099,161
Ensembl chr 8:51,093,441...51,099,157
|
|
G |
Cryz |
crystallin zeta |
decreases response to substance increases expression |
ISO |
CRYZ protein results in decreased susceptibility to tert-Butylhydroperoxide tert-Butylhydroperoxide results in increased expression of CRYZ mRNA |
CTD |
PMID:14729362 PMID:15003993 PMID:15336504 |
|
NCBI chr 2:243,552,037...243,580,369
Ensembl chr 2:243,552,119...243,579,758
|
|
G |
Csf1 |
colony stimulating factor 1 |
decreases response to substance |
ISO |
CSF1 protein results in decreased susceptibility to tert-Butylhydroperoxide |
CTD |
PMID:16446085 |
|
NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Csnk1d |
casein kinase 1, delta |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CSNK1D mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:106,221,992...106,256,620
Ensembl chr10:106,221,992...106,256,614
|
|
G |
Cspg4 |
chondroitin sulfate proteoglycan 4 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CSPG4 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 8:57,264,962...57,300,010
Ensembl chr 8:57,264,962...57,300,010
|
|
G |
Ctdspl |
CTD small phosphatase like |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CTDSPL mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 8:118,642,729...118,767,238
Ensembl chr 8:118,642,672...118,767,117
|
|
G |
Cth |
cystathionine gamma-lyase |
increases activity |
EXP |
tert-Butylhydroperoxide results in increased activity of CTH protein |
CTD |
PMID:18184479 |
|
NCBI chr 2:246,975,888...247,002,234
Ensembl chr 2:246,975,894...247,002,234
|
|
G |
Ctnna1 |
catenin alpha 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CTNNA1 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr18:26,728,246...26,860,911
Ensembl chr18:26,728,485...26,860,910
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions increases expression |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of CTNNB1 mRNA; [rosiglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of CTNNB1 mRNA; [troglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of CTNNB1 mRNA; rosiglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of CTNNB1 mRNA]; troglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of CTNNB1 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ctsb |
cathepsin B |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CTSB mRNA |
CTD |
PMID:15336504 |
|
NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Ctsl |
cathepsin L |
increases expression decreases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CTSL mRNA tert-Butylhydroperoxide results in decreased expression of CTSL mRNA |
CTD |
PMID:12419474 PMID:15336504 |
|
NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548
|
|
G |
Cttn |
cortactin |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CTTN mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 1:199,599,710...199,635,254
Ensembl chr 1:199,599,710...199,635,164
|
|
G |
Cul3 |
cullin 3 |
multiple interactions increases expression |
ISO |
Curcumin inhibits the reaction [tert-Butylhydroperoxide results in increased expression of CUL3 mRNA]; salvianolic acid B inhibits the reaction [tert-Butylhydroperoxide results in increased expression of CUL3 mRNA]; salvianolic acid B inhibits the reaction [tert-Butylhydroperoxide results in increased expression of CUL3 protein] tert-Butylhydroperoxide results in increased expression of CUL3 mRNA; tert-Butylhydroperoxide results in increased expression of CUL3 protein |
CTD |
PMID:38272317 |
|
NCBI chr 9:81,592,641...81,670,428
Ensembl chr 9:81,592,641...81,670,462
|
|
G |
Cul4a |
cullin 4A |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CUL4A mRNA |
CTD |
PMID:15336504 |
|
NCBI chr16:76,385,298...76,422,316
Ensembl chr16:76,384,546...76,422,330
|
|
G |
Cux1 |
cut-like homeobox 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CUX1 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr12:20,107,062...20,425,868
Ensembl chr12:20,107,311...20,425,866 Ensembl chr 4:20,107,311...20,425,866
|
|
G |
Cxadr |
CXADR, Ig-like cell adhesion molecule |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CXADR mRNA |
CTD |
PMID:15336504 |
|
NCBI chr11:16,982,864...17,030,078
Ensembl chr11:16,982,860...17,030,046
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CXCL1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CXCL10 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CXCL2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CXCL1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
multiple interactions increases expression |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of CXCR4 mRNA; [rosiglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of CXCR4 mRNA; [troglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of CXCR4 mRNA; rosiglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of CXCR4 mRNA]; tert-Butylhydroperoxide promotes the reaction [PPARG protein binds to CXCR4 promoter]; troglitazone inhibits the reaction [tert-Butylhydroperoxide promotes the reaction [PPARG protein binds to CXCR4 promoter]]; troglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of CXCR4 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Cxxc5 |
CXXC finger protein 5 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CXXC5 mRNA |
CTD |
PMID:29432895 |
|
NCBI chr18:27,427,591...27,458,579
Ensembl chr18:27,427,230...27,458,673
|
|
G |
Cyb561 |
cytochrome b-561 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CYB561 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:90,878,052...90,888,734
Ensembl chr10:90,878,054...90,884,787
|
|
G |
Cyb5d2 |
cytochrome b5 domain containing 2 |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of CYB5D2 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr10:57,394,268...57,413,336
Ensembl chr10:57,396,765...57,413,715
|
|
G |
Cyb5r2 |
cytochrome b5 reductase 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CYB5R2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:161,655,862...161,664,359
Ensembl chr 1:161,655,864...161,664,097
|
|
G |
Cybc1 |
cytochrome b-245 chaperone 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CYBC1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:106,498,730...106,505,549
Ensembl chr10:106,498,725...106,505,596
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization multiple interactions |
ISO |
tert-Butylhydroperoxide affects the localization of CYCS protein hyperoside inhibits the reaction [tert-Butylhydroperoxide affects the localization of CYCS protein] |
CTD |
PMID:18552516 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cygb |
cytoglobin |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CYGB mRNA |
CTD |
PMID:27509014 |
|
NCBI chr10:101,877,675...101,887,442
Ensembl chr10:101,877,676...101,887,442
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CYP1B1 mRNA |
CTD |
PMID:12414654 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp24a1 |
cytochrome P450, family 24, subfamily a, polypeptide 1 |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of CYP24A1 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr 3:159,275,947...159,290,383
Ensembl chr 3:159,275,947...159,290,383
|
|
G |
Cyria |
CYFIP related Rac1 interactor A |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CYRIA mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 6:35,045,208...35,150,669
Ensembl chr 6:35,045,208...35,150,668
|
|
G |
Dap3 |
death associated protein 3 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of DAP3 mRNA |
CTD |
PMID:14729362 |
|
NCBI chr 2:174,319,341...174,347,489
Ensembl chr 2:174,318,983...174,346,461
|
|
G |
Dapk1 |
death associated protein kinase 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DAPK1 mRNA |
CTD |
PMID:12419474 PMID:15336504 |
|
NCBI chr17:3,930,223...4,090,991
Ensembl chr17:3,930,213...4,090,991
|
|
G |
Dars1 |
aspartyl-tRNA synthetase 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of DARS1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr13:39,857,936...39,913,055
Ensembl chr13:39,857,936...39,913,116
|
|
G |
Dazap2 |
DAZ associated protein 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DAZAP2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:131,714,749...131,720,266
Ensembl chr 7:131,714,745...131,720,265
|
|
G |
Dbi |
diazepam binding inhibitor |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DBI mRNA |
CTD |
PMID:15336504 |
|
NCBI chr13:31,241,466...31,249,853
Ensembl chr13:31,206,988...31,268,693
|
|
G |
Dcaf7 |
DDB1 and CUL4 associated factor 7 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DCAF7 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:90,974,095...90,996,275
Ensembl chr10:90,974,095...90,996,275
|
|
G |
Dctn5 |
dynactin subunit 5 |
decreases methylation |
ISO |
tert-Butylhydroperoxide results in decreased methylation of DCTN5 gene |
CTD |
PMID:29432895 |
|
NCBI chr 1:176,689,176...176,705,907
Ensembl chr 1:176,689,156...176,705,906
|
|
G |
Ddb2 |
damage specific DNA binding protein 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of DDB2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:77,185,114...77,207,650
Ensembl chr 3:77,185,109...77,207,631
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO EXP |
tert-Butylhydroperoxide results in increased expression of DDIT3 mRNA; tert-Butylhydroperoxide results in increased expression of DDIT3 protein Acetylcysteine inhibits the reaction [tert-Butylhydroperoxide results in increased expression of DDIT3 protein]; ETFA mutant form inhibits the reaction [tert-Butylhydroperoxide results in increased expression of DDIT3 protein] |
CTD |
PMID:12414654 PMID:22659508 PMID:24394546 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of DDIT4 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105
|
|
G |
Ddr1 |
discoidin domain receptor tyrosine kinase 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DDR1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr20:3,042,494...3,064,442
Ensembl chr20:3,044,320...3,064,468
|
|
G |
Ddx11 |
DEAD/H-box helicase 11 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DDX11 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 9:105,833,234...105,862,844
Ensembl chr 9:105,833,504...105,862,550
|
|
G |
Ddx21 |
DExD-box helicase 21 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of DDX21 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr20:30,534,319...30,554,513
Ensembl chr20:30,534,319...30,554,543
|
|
G |
Ddx42 |
DEAD-box helicase 42 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of DDX42 mRNA |
CTD |
PMID:12414654 |
|
NCBI chr10:91,148,926...91,180,940
Ensembl chr10:91,148,254...91,180,939
|
|
G |
Ddx43 |
DEAD-box helicase 43 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of DDX43 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 8:79,255,001...79,284,468
Ensembl chr 8:79,255,655...79,284,453
|
|
G |
Ddx50 |
DExD-box helicase 50 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DDX50 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr20:30,561,623...30,591,324
Ensembl chr20:30,560,544...30,591,152
|
|
G |
Ddx52 |
DExD-box helicase 52 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of DDX52 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:68,824,594...68,847,400
Ensembl chr10:68,824,645...68,848,266
|
|
G |
Ddx56 |
DEAD-box helicase 56 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of DDX56 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr14:81,112,008...81,122,331
Ensembl chr14:81,112,012...81,122,333
|
|
G |
Ddx6 |
DEAD-box helicase 6 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of DDX6 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 8:44,931,127...44,967,773
Ensembl chr 8:44,931,974...44,964,405 Ensembl chr 8:44,931,974...44,964,405
|
|
G |
Dennd3 |
DENN domain containing 3 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DENND3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:105,415,870...105,473,583
Ensembl chr 7:105,415,677...105,473,592
|
|
G |
Depp1 |
DEPP autophagy regulator 1 |
multiple interactions increases expression |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of DEPP1 mRNA; [rosiglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of DEPP1 mRNA; [troglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of DEPP1 mRNA; pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of DEPP1 mRNA]; troglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of DEPP1 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr 4:149,910,794...149,913,013
Ensembl chr 4:149,910,779...149,914,542
|
|
G |
Derl1 |
derlin 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DERL1 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 7:89,404,413...89,427,095
Ensembl chr 7:89,404,417...89,427,145
|
|
G |
Dffb |
DNA fragmentation factor subunit beta |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DFFB mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 5:164,522,446...164,534,733
Ensembl chr 5:164,522,463...164,534,628
|
|
G |
Dgat2 |
diacylglycerol O-acyltransferase 2 |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of DGAT2 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr 1:153,454,078...153,484,432
Ensembl chr 1:153,454,080...153,484,428
|
|
G |
Dhps |
deoxyhypusine synthase |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DHPS mRNA |
CTD |
PMID:15336504 |
|
NCBI chr19:23,082,454...23,086,544
Ensembl chr19:23,082,448...23,086,881
|
|
G |
Dhx9 |
DExH-box helicase 9 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DHX9 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr13:65,602,322...65,639,098
Ensembl chr13:65,602,323...65,639,069
|
|
G |
Dimt1 |
DIM1 rRNA methyltransferase and ribosome maturation factor |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DIMT1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 2:38,343,086...38,368,242
Ensembl chr 2:38,354,854...38,368,227
|
|
G |
Dip2c |
disco-interacting protein 2 homolog C |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DIP2C mRNA |
CTD |
PMID:15336504 |
|
NCBI chr17:60,647,346...61,032,467
Ensembl chr17:60,649,065...61,032,305
|
|
G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of DKK1 mRNA |
CTD |
PMID:12414654 PMID:15336504 |
|
NCBI chr 1:228,381,521...228,385,202
Ensembl chr 1:228,381,521...228,385,202
|
|
G |
Dlg1 |
discs large MAGUK scaffold protein 1 |
multiple interactions increases expression |
ISO |
[rosiglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of DLG1 mRNA; [troglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of DLG1 mRNA; pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of DLG1 mRNA]; rosiglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of DLG1 mRNA]; troglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of DLG1 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr11:68,911,883...69,103,230
Ensembl chr11:68,911,883...69,102,689
|
|
G |
Dlg3 |
discs large MAGUK scaffold protein 3 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DLG3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr X:65,859,653...65,911,887
Ensembl chr X:65,860,172...65,910,322
|
|
G |
Dlgap4 |
DLG associated protein 4 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of DLGAP4 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:145,124,189...145,271,791
Ensembl chr 3:145,175,479...145,270,490
|
|
G |
Dlgap5 |
DLG associated protein 5 |
increases expression affects expression |
ISO |
tert-Butylhydroperoxide results in increased expression of DLGAP5 mRNA tert-Butylhydroperoxide affects the expression of DLGAP5 mRNA |
CTD |
PMID:15003993 PMID:23410634 |
|
NCBI chr15:20,633,964...20,664,569
Ensembl chr15:20,633,966...20,664,518
|
|
G |
Dlx2 |
distal-less homeobox 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of DLX2 mRNA |
CTD |
PMID:14729362 PMID:29432895 |
|
NCBI chr 3:56,370,238...56,373,581
Ensembl chr 3:56,370,483...56,373,597
|
|
G |
Dmpk |
DM1 protein kinase |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of DMPK mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 1:78,730,255...78,740,585
Ensembl chr 1:78,730,275...78,740,593
|
|
G |
Dnaaf2 |
dynein, axonemal, assembly factor 2 |
multiple interactions decreases expression |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of DNAAF2 mRNA; [rosiglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of DNAAF2 mRNA; [troglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of DNAAF2 mRNA; pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of DNAAF2 mRNA]; troglitazone inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of DNAAF2 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr 6:87,661,101...87,670,267
Ensembl chr 6:87,660,821...87,670,199
|
|
G |
Dnajb1 |
DnaJ heat shock protein family (Hsp40) member B1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DNAJB1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr19:24,522,731...24,526,419
Ensembl chr19:24,522,717...24,526,458
|
|
G |
Dnajb11 |
DnaJ heat shock protein family (Hsp40) member B11 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DNAJB11 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr11:78,151,750...78,168,259
Ensembl chr11:78,150,429...78,180,407
|
|
G |
Dnajb4 |
DnaJ heat shock protein family (Hsp40) member B4 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DNAJB4 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 2:241,129,346...241,159,272
Ensembl chr 2:241,130,340...241,159,089
|
|
G |
Dnajb7 |
DnaJ heat shock protein family (Hsp40) member B7 |
decreases methylation |
ISO |
tert-Butylhydroperoxide results in decreased methylation of DNAJB7 intron |
CTD |
PMID:29432895 |
|
NCBI chr 7:112,932,736...112,934,050
Ensembl chr 7:112,932,616...112,945,537
|
|
G |
Dnase2 |
deoxyribonuclease 2, lysosomal |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DNASE2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr19:23,244,656...23,247,376
Ensembl chr19:23,244,664...23,247,376
|
|
G |
Dnm2 |
dynamin 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DNM2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 8:19,978,313...20,060,162
Ensembl chr 8:19,978,400...20,060,157
|
|
G |
Dnmbp |
dynamin binding protein |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of DNMBP mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:242,736,189...242,829,431
Ensembl chr 1:242,736,189...242,802,604
|
|
G |
Dnph1 |
2'-deoxynucleoside 5'-phosphate N-hydrolase 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DNPH1 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 9:14,481,296...14,484,034
Ensembl chr 9:14,481,066...14,484,022
|
|
G |
Dock2 |
dedicator of cytokinesis 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DOCK2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:18,827,237...19,244,832
Ensembl chr10:18,827,239...19,244,808
|
|
G |
Dock4 |
dedicator of cytokinesis 4 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of DOCK4 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 6:57,512,929...57,902,597
Ensembl chr 6:57,512,908...57,901,855
|
|
G |
Dpp4 |
dipeptidylpeptidase 4 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of DPP4 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:46,962,233...47,043,870
Ensembl chr 3:46,962,243...47,043,901
|
|
G |
Dpy19l1 |
dpy-19 like C-mannosyltransferase 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DPY19L1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 8:22,933,163...23,021,461
Ensembl chr 8:22,933,163...23,021,751
|
|
G |
Dpysl3 |
dihydropyrimidinase-like 3 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of DPYSL3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr18:35,374,427...35,480,228
Ensembl chr18:35,377,181...35,480,157
|
|
G |
Drap1 |
Dr1 associated protein 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of DRAP1 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 1:202,731,775...202,734,468
Ensembl chr 1:202,731,788...202,734,425
|
|
G |
Dsc3 |
desmocollin 3 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DSC3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr18:11,379,759...11,413,797
Ensembl chr18:11,377,347...11,413,797
|
|
G |
Dst |
dystonin |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DST mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 9:36,135,657...36,529,617
Ensembl chr 9:36,135,284...36,529,615
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of DUSP1 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr10:16,680,478...16,683,275
|
|
G |
Dusp10 |
dual specificity phosphatase 10 |
multiple interactions increases expression |
ISO |
[Pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of DUSP10 mRNA; [Rosiglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of DUSP10 mRNA; [Troglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of DUSP10 mRNA; Rosiglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of DUSP10 mRNA]; Troglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of DUSP10 mRNA] |
CTD |
PMID:15336504 PMID:20847119 |
|
NCBI chr13:95,613,716...95,651,716
Ensembl chr13:95,614,292...95,651,716
|
|
G |
Dusp5 |
dual specificity phosphatase 5 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of DUSP5 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:252,538,408...252,555,320
Ensembl chr 1:252,538,449...252,551,818
|
|
G |
Dusp6 |
dual specificity phosphatase 6 |
decreases expression increases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DUSP6 mRNA tert-Butylhydroperoxide results in increased expression of DUSP6 mRNA |
CTD |
PMID:15336504 PMID:17003459 |
|
NCBI chr 7:34,092,848...34,097,186
Ensembl chr 7:34,092,943...34,097,185
|
|
G |
Dusp9 |
dual specificity phosphatase 9 |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of DUSP9 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr X:151,351,897...151,355,822
Ensembl chr X:151,351,897...151,355,821
|
|
G |
Dut |
deoxyuridine triphosphatase |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DUT mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:112,498,864...112,509,994
Ensembl chr 3:112,498,982...112,510,771
|
|
G |
Dvl3 |
dishevelled segment polarity protein 3 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DVL3 mRNA |
CTD |
PMID:29432895 |
|
NCBI chr11:80,365,446...80,382,641
Ensembl chr11:80,366,117...80,382,462
|
|
G |
Dynll1 |
dynein light chain LC8-type 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DYNLL1 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr12:41,312,365...41,316,157
Ensembl chr12:41,312,367...41,314,741
|
|
G |
Dynlrb1 |
dynein light chain roadblock-type 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DYNLRB1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:143,742,427...143,764,227
Ensembl chr 3:143,742,586...143,764,227
|
|
G |
E2f1 |
E2F transcription factor 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of E2F1 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
Ech1 |
enoyl-CoA hydratase 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ECH1 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 1:84,114,494...84,120,788
Ensembl chr 1:84,112,751...84,120,795
|
|
G |
Echdc2 |
enoyl CoA hydratase domain containing 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ECHDC2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 5:122,915,874...122,934,860
Ensembl chr 5:122,916,134...122,934,859
|
|
G |
Echs1 |
enoyl-CoA hydratase, short chain 1 |
decreases expression |
EXP |
tert-Butylhydroperoxide results in decreased expression of ECHS1 protein |
CTD |
PMID:24394546 |
|
NCBI chr 1:194,895,036...194,903,863
Ensembl chr 1:194,895,036...194,903,884
|
|
G |
Eci1 |
enoyl-CoA delta isomerase 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ECI1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:13,456,715...13,470,061
Ensembl chr10:13,456,563...13,470,061
|
|
G |
Ecsit |
ECSIT signaling integrator |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ECSIT mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 8:20,605,583...20,618,453
Ensembl chr 8:20,605,583...20,618,390
|
|
G |
Edil3 |
EGF like repeats and discoidin domains 3 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of EDIL3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 2:19,890,396...20,405,028
Ensembl chr 2:19,890,373...20,405,008
|
|
G |
Edn1 |
endothelin 1 |
increases expression affects expression |
ISO |
tert-Butylhydroperoxide results in increased expression of EDN1 mRNA tert-Butylhydroperoxide affects the expression of EDN1 mRNA |
CTD |
PMID:12414654 PMID:23410634 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Eef2 |
eukaryotic translation elongation factor 2 |
decreases expression |
EXP |
tert-Butylhydroperoxide results in decreased expression of EEF2 protein |
CTD |
PMID:16469450 |
|
NCBI chr 7:8,533,248...8,538,518
Ensembl chr 7:8,533,116...8,559,183
|
|
G |
Efemp1 |
EGF containing fibulin extracellular matrix protein 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of EFEMP1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr14:102,610,813...102,690,027
Ensembl chr14:102,610,908...102,690,018
|
|
G |
Efhd1 |
EF-hand domain family, member D1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of EFHD1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 9:87,938,259...87,984,917
Ensembl chr 9:87,938,284...87,984,917
|
|
G |
Efna4 |
ephrin A4 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of EFNA4 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 2:174,748,729...174,752,979
Ensembl chr 2:174,748,724...174,752,979
|
|
G |
Efs |
embryonal Fyn-associated substrate |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of EFS mRNA |
CTD |
PMID:15336504 |
|
NCBI chr15:28,392,417...28,403,016
Ensembl chr15:28,392,187...28,401,902
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of EGFR mRNA; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of EGFR mRNA] |
CTD |
PMID:35690295 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egr1 |
early growth response 1 |
increases expression affects expression |
ISO |
tert-Butylhydroperoxide results in increased expression of EGR1 mRNA tert-Butylhydroperoxide affects the expression of EGR1 mRNA |
CTD |
PMID:12414654 PMID:23410634 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Eif2ak2 |
eukaryotic translation initiation factor 2-alpha kinase 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of EIF2AK2 mRNA |
CTD |
PMID:14729362 PMID:15003993 |
|
NCBI chr 6:16,189,000...16,224,972
Ensembl chr 6:16,188,979...16,224,971
|
|
G |
Eif2b4 |
eukaryotic translation initiation factor 2B subunit delta |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of EIF2B4 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 6:25,183,177...25,188,832
Ensembl chr 6:25,183,186...25,188,829
|
|
G |
Eif3m |
eukaryotic translation initiation factor 3, subunit M |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of EIF3M mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:91,424,754...91,442,358
Ensembl chr 3:91,416,325...91,442,392
|
|
G |
Eif5 |
eukaryotic translation initiation factor 5 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of EIF5 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 6:130,589,162...130,597,656
Ensembl chr 6:130,589,143...130,597,656
|
|
G |
Eif5b |
eukaryotic translation initiation factor 5B |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of EIF5B mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 9:40,222,769...40,277,482
Ensembl chr 9:40,222,898...40,277,482
|
|
G |
Elavl1 |
ELAV like RNA binding protein 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ELAVL1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr12:2,640,936...2,684,787
Ensembl chr12:2,645,061...2,684,784
|
|
G |
Elf1 |
E74 like ETS transcription factor 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ELF1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr15:54,890,644...54,986,721
Ensembl chr15:54,865,616...54,986,699
|
|
G |
Elf5 |
E74 like ETS transcription factor 5 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ELF5 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 3:89,808,837...89,836,977
Ensembl chr 3:89,797,880...89,836,973
|
|
G |
Elob |
elongin B |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ELOB mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:12,848,830...12,853,897
Ensembl chr10:12,848,827...12,853,635
|
|
G |
Eme1 |
essential meiotic structure-specific endonuclease 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of EME1 mRNA |
CTD |
PMID:27509014 |
|
NCBI chr10:79,586,718...79,595,515
Ensembl chr10:79,586,729...79,595,435
|
|
G |
Emilin1 |
elastin microfibril interfacer 1 |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of EMILIN1 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr 6:25,455,974...25,463,713
Ensembl chr 6:25,445,298...25,463,698
|
|
G |
Eml1 |
EMAP like 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of EML1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 6:127,283,968...127,457,246
Ensembl chr 6:127,284,029...127,457,246
|
|
G |
Eml4 |
EMAP like 4 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of EML4 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 6:11,219,545...11,334,824
Ensembl chr 6:11,219,566...11,334,879
|
|
G |
Emp3 |
epithelial membrane protein 3 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of EMP3 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 1:96,388,651...96,391,946
Ensembl chr 1:96,388,652...96,391,988
|
|
G |
Eng |
endoglin |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ENG mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:15,934,566...15,972,618
Ensembl chr 3:15,934,518...15,973,230
|
|
G |
Epb41l2 |
erythrocyte membrane protein band 4.1-like 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of EPB41L2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:19,863,010...20,037,795
Ensembl chr 1:19,863,009...20,037,721
|
|
G |
Epb42 |
erythrocyte membrane protein band 4.2 |
increases degradation |
ISO |
tert-Butylhydroperoxide results in increased degradation of EPB42 protein |
CTD |
PMID:15040847 |
|
NCBI chr 3:107,979,709...107,997,932
Ensembl chr 3:107,979,713...107,997,932
|
|
G |
Ephb2 |
Eph receptor B2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of EPHB2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 5:148,889,574...149,077,027
Ensembl chr 5:148,897,246...149,077,059
|
|
G |
Ephb4 |
EPH receptor B4 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of EPHB4 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr12:19,326,411...19,351,667
Ensembl chr12:19,326,427...19,351,314
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of EPHX1 mRNA |
CTD |
PMID:21382384 |
|
NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of EPHX2 mRNA |
CTD |
PMID:14729362 |
|
NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ERBB2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Erbb4 |
erb-b2 receptor tyrosine kinase 4 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ERBB4 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 9:69,523,733...70,596,743
Ensembl chr 9:69,531,481...70,596,595
|
|
G |
Erbin |
erbb2 interacting protein |
multiple interactions increases expression |
ISO |
[troglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of ERBIN mRNA; pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ERBIN mRNA]; rosiglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ERBIN mRNA]; troglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ERBIN mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr 2:34,926,962...35,028,440
Ensembl chr 2:34,928,863...35,027,852
|
|
G |
Ercc5 |
ERCC excision repair 5, endonuclease |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ERCC5 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 9:46,309,477...46,354,478
Ensembl chr 9:46,309,389...46,354,472
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions |
ISO |
Acetylcysteine inhibits the reaction [tert-Butylhydroperoxide promotes the reaction [ERN1 protein binds to TRAF2 protein]]; ETFA mutant form inhibits the reaction [tert-Butylhydroperoxide promotes the reaction [ERN1 protein binds to TRAF2 protein]]; tert-Butylhydroperoxide promotes the reaction [ERN1 protein binds to TRAF2 protein] |
CTD |
PMID:24394546 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Erp29 |
endoplasmic reticulum protein 29 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ERP29 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr12:35,089,698...35,095,952
Ensembl chr12:35,089,707...35,096,376
|
|
G |
Esm1 |
endothelial cell-specific molecule 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ESM1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 2:44,876,067...44,884,805
Ensembl chr 2:44,876,067...44,884,804
|
|
G |
Ess2 |
ess-2 splicing factor homolog |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ESS2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr11:83,075,893...83,085,849
Ensembl chr11:83,075,925...83,084,846
|
|
G |
Etf1 |
eukaryotic translation termination factor 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ETF1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr18:26,502,413...26,530,753
Ensembl chr18:26,504,080...26,530,810
|
|
G |
Etfa |
electron transfer flavoprotein subunit alpha |
multiple interactions decreases expression increases expression |
ISO EXP |
ETFA mutant form inhibits the reaction [tert-Butylhydroperoxide promotes the reaction [ERN1 protein binds to TRAF2 protein]]; ETFA mutant form inhibits the reaction [tert-Butylhydroperoxide results in increased expression of DDIT3 protein]; ETFA mutant form inhibits the reaction [tert-Butylhydroperoxide results in increased expression of NFKB1 protein]; pyrazolanthrone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ETFA protein] tert-Butylhydroperoxide results in decreased expression of ETFA protein |
CTD |
PMID:24394546 |
|
NCBI chr 8:55,835,115...55,891,890
Ensembl chr 8:55,835,134...55,891,969
|
|
G |
Etfb |
electron transfer flavoprotein subunit beta |
decreases expression increases methylation |
ISO |
tert-Butylhydroperoxide results in decreased expression of ETFB mRNA tert-Butylhydroperoxide results in increased methylation of ETFB gene |
CTD |
PMID:15336504 PMID:29432895 |
|
NCBI chr 1:93,851,908...93,866,072
Ensembl chr 1:93,851,858...93,866,068
|
|
G |
Ets1 |
ETS proto-oncogene 1, transcription factor |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ETS1 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 8:31,045,909...31,168,010
Ensembl chr 8:31,045,945...31,168,010
|
|
G |
Ets2 |
ETS proto-oncogene 2, transcription factor |
decreases expression increases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ETS2 mRNA tert-Butylhydroperoxide results in increased expression of ETS2 mRNA |
CTD |
PMID:12419474 PMID:15336504 |
|
NCBI chr11:35,021,536...35,038,322
Ensembl chr11:35,021,596...35,038,319
|
|
G |
Etv3 |
ETS variant transcription factor 3 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ETV3 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 2:172,965,461...172,980,320
Ensembl chr 2:172,965,588...172,980,314
|
|
G |
Etv4 |
ETS variant transcription factor 4 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ETV4 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr10:86,706,749...86,721,974
Ensembl chr10:86,706,749...86,721,974
|
|
G |
Etv5 |
ETS variant transcription factor 5 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ETV5 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr11:78,608,618...78,666,221
Ensembl chr11:78,608,710...78,666,215
|
|
G |
Exo1 |
exonuclease 1 |
multiple interactions |
ISO |
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of EXO1 mRNA; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of EXO1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of EXO1 mRNA] |
CTD |
PMID:35690295 |
|
NCBI chr13:87,809,725...87,834,654
Ensembl chr13:87,809,810...87,834,654
|
|
G |
Exoc7 |
exocyst complex component 7 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of EXOC7 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:101,521,630...101,540,425
Ensembl chr10:101,520,927...101,540,561
|
|
G |
Ezh2 |
enhancer of zeste 2 polycomb repressive complex 2 subunit |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of EZH2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:76,624,399...76,687,362
Ensembl chr 4:76,624,399...76,687,362
|
|
G |
Ezr |
ezrin |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of EZR mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 1:46,967,961...47,011,505
Ensembl chr 1:46,967,658...47,011,505
|
|
G |
F2rl1 |
F2R like trypsin receptor 1 |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of F2RL1 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr 2:26,772,274...26,785,226
Ensembl chr 2:26,772,278...26,785,226
|
|
G |
Fah |
fumarylacetoacetate hydrolase |
decreases expression |
EXP |
tert-Butylhydroperoxide results in decreased expression of FAH protein |
CTD |
PMID:24394546 |
|
NCBI chr 1:138,548,830...138,571,599
Ensembl chr 1:138,548,834...138,571,505
|
|
G |
Fam110b |
family with sequence similarity 110, member B |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of FAM110B mRNA |
CTD |
PMID:29432895 |
|
NCBI chr 5:18,789,362...18,929,647
Ensembl chr 5:18,789,389...18,929,828
|
|
G |
Fam111a |
FAM111 trypsin like peptidase A |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of FAM111A mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:209,640,865...209,656,551
Ensembl chr 1:209,640,953...209,656,547
|
|
G |
Fam13b |
family with sequence similarity 13, member B |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of FAM13B mRNA |
CTD |
PMID:15003993 |
|
NCBI chr18:26,040,285...26,107,112
Ensembl chr18:26,040,285...26,106,587
|
|
G |
Fam171a1 |
family with sequence similarity 171, member A1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of FAM171A1 mRNA |
CTD |
PMID:29432895 |
|
NCBI chr17:75,024,582...75,148,348
Ensembl chr17:75,024,575...75,150,255
|
|
G |
Fam210a |
family with sequence similarity 210, member A |
multiple interactions increases expression |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of FAM210A mRNA; [rosiglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of FAM210A mRNA; [troglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of FAM210A mRNA; rosiglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of FAM210A mRNA]; troglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of FAM210A mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr18:61,846,447...61,886,123
Ensembl chr18:61,852,907...61,886,171
|
|
G |
Fanci |
FA complementation group I |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of FANCI mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:133,327,264...133,383,661
Ensembl chr 1:133,327,297...133,383,640
|
|
G |
Farp1 |
FERM, ARH/RhoGEF and pleckstrin domain protein 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of FARP1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr15:98,124,304...98,363,299
Ensembl chr15:98,182,329...98,363,299
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of FAS mRNA |
CTD |
PMID:12414654 PMID:27509014 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fastk |
Fas-activated serine/threonine kinase |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of FASTK mRNA |
CTD |
PMID:12419474 PMID:15336504 |
|
NCBI chr 4:10,732,273...10,736,332
Ensembl chr 4:10,732,256...10,737,430
|
|
G |
Fbln1 |
fibulin 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of FBLN1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:116,310,582...116,390,075
Ensembl chr 7:116,310,582...116,390,075
|
|
G |
Fbxo30 |
F-box protein 30 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of FBXO30 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr 1:5,655,341...5,671,558
Ensembl chr 1:5,655,339...5,672,441
|
|
G |
Fdps |
farnesyl diphosphate synthase |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of FDPS mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 2:174,497,402...174,507,031
Ensembl chr 2:174,486,665...174,507,776
|
|
G |
Fdx1 |
ferredoxin 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of FDX1 mRNA |
CTD |
PMID:14729362 PMID:15336504 |
|
NCBI chr 8:52,268,536...52,287,344
Ensembl chr 8:52,268,536...52,287,414
|
|
G |
Fdxr |
ferredoxin reductase |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of FDXR mRNA |
CTD |
PMID:12414654 PMID:27509014 |
|
NCBI chr10:100,507,863...100,516,649
Ensembl chr10:100,507,865...100,516,658
|
|
G |
Fen1 |
flap structure-specific endonuclease 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of FEN1 mRNA |
CTD |
PMID:12414654 PMID:15336504 |
|
NCBI chr 1:206,845,126...206,849,821
Ensembl chr 1:206,844,884...206,850,003
|
|
G |
Fermt2 |
FERM domain containing kindlin 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of FERMT2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr15:18,682,927...18,751,959
Ensembl chr15:18,682,927...18,751,811
|
|
G |
Fgg |
fibrinogen gamma chain |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of FGG mRNA |
CTD |
PMID:12414654 |
|
NCBI chr 2:168,354,880...168,362,325
Ensembl chr 2:168,355,013...168,362,322
|
|
G |
Fh |
fumarate hydratase |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of FH mRNA |
CTD |
PMID:15336504 |
|
NCBI chr13:87,524,331...87,550,215
Ensembl chr13:87,524,337...87,550,266
|
|
G |
Fhl1 |
four and a half LIM domains 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of FHL1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr X:134,555,399...134,614,930
Ensembl chr X:134,555,479...134,614,928
|
|
G |
Fhl2 |
four and a half LIM domains 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of FHL2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 9:45,388,979...45,462,421
Ensembl chr 9:45,388,981...45,431,192
|
|
G |
Fhod3 |
formin homology 2 domain containing 3 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of FHOD3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr18:15,993,079...16,425,796
Ensembl chr18:15,993,324...16,425,796
|
|
G |
Fibp |
FGF1 intracellular binding protein |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of FIBP mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:202,768,065...202,772,405
Ensembl chr 1:202,768,078...202,772,399
|
|
G |
Fis1 |
fission, mitochondrial 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of FIS1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr12:19,708,560...19,723,392
Ensembl chr12:19,708,558...19,723,377
|
|
G |
Fjx1 |
four-jointed box kinase 1 |
multiple interactions decreases expression |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of FJX1 mRNA; [rosiglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of FJX1 mRNA; [troglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of FJX1 mRNA; troglitazone inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of FJX1 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr 3:88,774,220...88,776,321
Ensembl chr 3:88,774,220...88,776,321
|
|
G |
Fkbp1a |
FKBP prolyl isomerase 1A |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of FKBP1A mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:140,040,359...140,060,107
Ensembl chr 3:140,040,278...140,060,743
|
|
G |
Fkbp8 |
FKBP prolyl isomerase 8 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of FKBP8 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr16:18,895,608...18,902,648
Ensembl chr16:18,893,576...18,902,612
|
|
G |
Flnb |
filamin B |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of FLNB mRNA |
CTD |
PMID:15336504 |
|
NCBI chr15:16,961,999...17,095,059
Ensembl chr15:16,962,003...17,095,006
|
|
G |
Fmo1 |
flavin containing dimethylaniline monoxygenase 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of FMO1 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647
|
|
G |
Fn1 |
fibronectin 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of FN1 mRNA |
CTD |
PMID:15963989 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Folr1 |
folate receptor alpha |
increases expression decreases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of FOLR1 mRNA tert-Butylhydroperoxide results in decreased expression of FOLR1 mRNA |
CTD |
PMID:14729362 PMID:15003993 PMID:22956110 |
|
NCBI chr 1:156,219,460...156,238,436
Ensembl chr 1:156,219,460...156,230,667
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
decreases expression increases methylation increases expression multiple interactions |
ISO |
tert-Butylhydroperoxide results in decreased expression of FOS mRNA tert-Butylhydroperoxide results in increased methylation of FOS gene tert-Butylhydroperoxide results in increased expression of FOS mRNA CAT protein inhibits the reaction [tert-Butylhydroperoxide results in increased expression of FOS mRNA]; Glutathione inhibits the reaction [tert-Butylhydroperoxide results in increased expression of FOS mRNA]; Thiourea inhibits the reaction [tert-Butylhydroperoxide results in increased expression of FOS mRNA] |
CTD |
PMID:12419474 PMID:15105052 PMID:27509014 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of FOSL1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930
|
|
G |
Foxd1 |
forkhead box D1 |
decreases expression increases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of FOXD1 mRNA tert-Butylhydroperoxide results in increased expression of FOXD1 mRNA |
CTD |
PMID:15003993 PMID:15336504 |
|
NCBI chr 2:29,702,558...29,704,978
Ensembl chr 2:29,702,558...29,704,978
|
|
G |
Foxm1 |
forkhead box M1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of FOXM1 mRNA |
CTD |
PMID:12414654 PMID:15336504 |
|
NCBI chr 4:161,639,538...161,652,012
Ensembl chr 4:161,638,816...161,650,684
|
|
G |
Ftl1 |
ferritin light chain 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of FTL mRNA |
CTD |
PMID:12414654 PMID:15963989 |
|
NCBI chr 1:95,936,387...95,938,234
Ensembl chr 1:95,936,387...95,939,725 Ensembl chr10:95,936,387...95,939,725 Ensembl chr 2:95,936,387...95,939,725
|
|
G |
Fubp1 |
far upstream element binding protein 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of FUBP1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 2:241,159,481...241,186,591
Ensembl chr 2:241,159,512...241,186,602
|
|
G |
Fxyd5 |
FXYD domain-containing ion transport regulator 5 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of FXYD5 mRNA |
CTD |
PMID:14729362 PMID:15003993 PMID:15336504 |
|
NCBI chr 1:86,267,937...86,277,329
Ensembl chr 1:86,267,406...86,277,519
|
|
G |
Fyco1 |
FYVE and coiled-coil domain autophagy adaptor 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of FYCO1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 8:123,412,105...123,479,315
Ensembl chr 8:123,412,112...123,479,021
|
|
G |
Fzd1 |
frizzled class receptor 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of FZD1 mRNA |
CTD |
PMID:29432895 |
|
NCBI chr 4:29,310,303...29,314,701
Ensembl chr 4:29,310,091...29,312,643 Ensembl chr 4:29,310,091...29,312,643
|
|
G |
Fzr1 |
fizzy and cell division cycle 20 related 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of FZR1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:8,332,029...8,343,953
Ensembl chr 7:8,332,029...8,343,952
|
|
G |
G0s2 |
G0/G1switch 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of G0S2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr13:104,806,351...104,807,263
Ensembl chr13:104,806,156...104,807,451
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
decreases activity increases activity |
ISO EXP |
tert-Butylhydroperoxide results in decreased activity of G6PD protein tert-Butylhydroperoxide results in increased activity of G6PD protein |
CTD |
PMID:12628296 PMID:15336504 PMID:16928893 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
decreases expression affects expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of GADD45B mRNA tert-Butylhydroperoxide affects the expression of GADD45B mRNA |
CTD |
PMID:15336504 PMID:23410634 |
|
NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046
|
|
G |
Gak |
cyclin G associated kinase |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of GAK mRNA |
CTD |
PMID:12419474 |
|
NCBI chr14:1,089,853...1,164,098
Ensembl chr14:1,089,866...1,216,398
|
|
G |
Galm |
galactose mutarotase |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of GALM mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 6:14,837,540...14,889,484
Ensembl chr 6:14,837,548...14,889,310
|
|
G |
Galns |
galactosamine (N-acetyl)-6-sulfatase |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of GALNS mRNA |
CTD |
PMID:15336504 |
|
NCBI chr19:50,628,639...50,662,477
Ensembl chr19:50,628,552...50,662,246
|
|
G |
Galnt1 |
polypeptide N-acetylgalactosaminyltransferase 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of GALNT1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr18:15,489,015...15,568,849
Ensembl chr18:15,489,020...15,568,245
|
|
G |
Galnt3 |
polypeptide N-acetylgalactosaminyltransferase 3 |
increases methylation decreases methylation |
ISO |
tert-Butylhydroperoxide results in increased methylation of GALNT3 intron tert-Butylhydroperoxide results in decreased methylation of GALNT3 intron |
CTD |
PMID:29432895 |
|
NCBI chr 3:50,742,500...50,779,266
Ensembl chr 3:50,742,512...50,766,268
|
|
G |
Galnt6 |
polypeptide N-acetylgalactosaminyltransferase 6 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of GALNT6 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:131,789,836...131,828,077
Ensembl chr 7:131,789,839...131,819,661
|
|
G |
Ganab |
glucosidase II alpha subunit |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of GANAB mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:205,793,910...205,813,704
Ensembl chr 1:205,793,895...205,813,695
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of GAPDH protein |
CTD |
PMID:11295360 |
|
NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
|
|
G |
Gars1 |
glycyl-tRNA synthetase 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of GARS1 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 4:84,171,596...84,212,609
Ensembl chr 4:84,171,596...84,212,609
|
|
G |
Gas2 |
growth arrest-specific 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of GAS2 mRNA |
CTD |
PMID:14729362 |
|
NCBI chr 1:101,452,361...101,582,619
Ensembl chr 1:101,482,591...101,582,619
|
|
G |
Gas2l1 |
growth arrest-specific 2 like 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of GAS2L1 mRNA |
CTD |
PMID:29432895 |
|
NCBI chr14:79,955,350...79,961,830
Ensembl chr14:79,950,555...79,961,438
|
|
G |
Gata6 |
GATA binding protein 6 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of GATA6 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr18:2,188,121...2,219,532
Ensembl chr18:2,188,121...2,219,532
|
|
G |
Gatd3a |
glutamine amidotransferase class 1 domain containing 3A |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of GATD3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr20:10,514,793...10,522,894
Ensembl chr20:10,514,744...10,522,885
|
|
G |
Gbp2 |
guanylate binding protein 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of GBP2 mRNA |
CTD |
PMID:14729362 PMID:15003993 |
|
NCBI chr 2:231,332,488...231,348,573
Ensembl chr 2:231,332,284...231,348,571
|
|
G |
Gbp4 |
guanylate binding protein 4 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of GBP3 mRNA |
CTD |
PMID:14729362 PMID:15003993 |
|
NCBI chr 2:231,304,910...231,318,883
Ensembl chr 2:231,305,244...231,318,879
|
|
G |
Gbp6 |
guanylate binding protein family member 6 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of GBP6 mRNA |
CTD |
PMID:14729362 PMID:15003993 |
|
NCBI chr14:4,730,286...4,756,508
Ensembl chr14:4,730,453...4,839,062 Ensembl chr14:4,730,453...4,839,062
|
|
G |
Gchfr |
GTP cyclohydrolase I feedback regulator |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of GCHFR mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:106,158,046...106,162,080
Ensembl chr 3:106,159,394...106,162,080
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions decreases expression increases expression decreases response to substance |
ISO EXP |
[Linoleic Acids, Conjugated results in increased activity of GCLC protein] which results in decreased susceptibility to tert-Butylhydroperoxide tert-Butylhydroperoxide results in decreased expression of GCLC mRNA tert-Butylhydroperoxide results in increased expression of GCLC mRNA [Apigenin results in increased expression of GCLC mRNA] which results in decreased susceptibility to tert-Butylhydroperoxide; [Buthionine Sulfoximine results in decreased activity of [GCLC protein binds to GCLM protein]] inhibits the reaction [chrysin inhibits the reaction [tert-Butylhydroperoxide results in increased chemical synthesis of Reactive Oxygen Species]]; [chrysin results in increased expression of GCLC mRNA] which results in decreased susceptibility to tert-Butylhydroperoxide; [Luteolin results in increased expression of GCLC mRNA] which results in decreased susceptibility to tert-Butylhydroperoxide GCLC protein results in decreased susceptibility to tert-Butylhydroperoxide |
CTD |
PMID:12425961 PMID:17092368 PMID:22864849 PMID:23410634 PMID:27509014 PMID:30547568 More...
|
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions increases expression |
EXP ISO |
[Apigenin results in increased expression of GCLM mRNA] which results in decreased susceptibility to tert-Butylhydroperoxide; [Buthionine Sulfoximine results in decreased activity of [GCLC protein binds to GCLM protein]] inhibits the reaction [chrysin inhibits the reaction [tert-Butylhydroperoxide results in increased chemical synthesis of Reactive Oxygen Species]]; [chrysin results in increased expression of GCLM mRNA] which results in decreased susceptibility to tert-Butylhydroperoxide tert-Butylhydroperoxide results in increased expression of GCLM mRNA |
CTD |
PMID:12414654 PMID:22864849 PMID:23410634 PMID:27509014 PMID:30547568 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gcnt1 |
glucosaminyl (N-acetyl) transferase 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of GCNT1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:214,718,344...214,755,735
Ensembl chr 1:214,718,293...214,758,776
|
|
G |
Gcnt3 |
glucosaminyl (N-acetyl) transferase 3, mucin type |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of GCNT3 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr 8:70,689,173...70,696,476
Ensembl chr 8:70,686,844...70,699,562
|
|
G |
Gdf15 |
growth differentiation factor 15 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of GDF15 mRNA |
CTD |
PMID:12414654 |
|
NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055
|
|
G |
Gdpd5 |
glycerophosphodiester phosphodiesterase domain containing 5 |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of GDPD5 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr 1:153,679,718...153,761,452
Ensembl chr 1:153,679,718...153,761,446
|
|
G |
Gem |
GTP binding protein overexpressed in skeletal muscle |
multiple interactions increases expression |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of GEM mRNA; [rosiglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of GEM mRNA; [troglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of GEM mRNA; troglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of GEM mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr 5:25,214,309...25,225,222
Ensembl chr 5:25,214,309...25,225,222
|
|
G |
Gemin4 |
gem (nuclear organelle) associated protein 4 |
multiple interactions decreases expression |
ISO |
[Pioglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of GEMIN4 mRNA; [Rosiglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of GEMIN4 mRNA; Troglitazone inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of GEMIN4 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr10:61,062,420...61,073,529
Ensembl chr10:61,066,425...61,073,431 Ensembl chr10:61,066,425...61,073,431
|
|
G |
Gfap |
glial fibrillary acidic protein |
decreases expression increases expression |
EXP |
tert-Butylhydroperoxide results in decreased expression of GFAP protein tert-Butylhydroperoxide results in increased expression of GFAP protein |
CTD |
PMID:24394546 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Gfer |
growth factor, augmenter of liver regeneration |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of GFER mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:13,718,489...13,721,782
Ensembl chr10:13,718,489...13,720,869
|
|
G |
Gfpt2 |
glutamine-fructose-6-phosphate transaminase 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of GFPT2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:34,115,005...34,161,329
Ensembl chr10:34,115,052...34,161,329
|
|
G |
Gfra1 |
GDNF family receptor alpha 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of GFRA1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:257,315,682...257,552,004
Ensembl chr 1:257,321,742...257,551,473
|
|
G |
Gins2 |
GINS complex subunit 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of GINS2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr19:48,626,770...48,639,523
Ensembl chr19:48,626,770...48,639,339
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
decreases expression decreases response to substance |
ISO |
tert-Butylhydroperoxide results in decreased expression of GJA1 mRNA; tert-Butylhydroperoxide results in decreased expression of GJA1 protein GJA1 protein results in decreased susceptibility to tert-Butylhydroperoxide |
CTD |
PMID:15336504 PMID:18235030 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Gjb2 |
gap junction protein, beta 2 |
decreases response to substance |
ISO |
GJB2 protein results in decreased susceptibility to tert-Butylhydroperoxide |
CTD |
PMID:18235030 |
|
NCBI chr15:31,260,390...31,278,222
Ensembl chr15:31,260,357...31,278,177
|
|
G |
Gla |
galactosidase, alpha |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of GLA mRNA |
CTD |
PMID:14729362 |
|
NCBI chr X:97,769,227...97,780,646
| |